BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-384. [PMID: 25795410 DOI: 10.1016/s1470-2045(15)70076-8] [Cited by in Crossref: 1853] [Cited by in F6Publishing: 1993] [Article Influence: 231.6] [Reference Citation Analysis]
Number Citing Articles
1 Shi H, Tang H, Li Y, Chen D, Liu T, Chen Y, Wang X, Chen L, Wang Y, Xie H, Xiong B. Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors. Eur J Med Chem 2023;248:115064. [PMID: 36621137 DOI: 10.1016/j.ejmech.2022.115064] [Reference Citation Analysis]
2 Hasan I, Loho IM, Setiawan PB, Djumhana A, Purnomo HD, Siregar L, Gani RA, Sulaiman AS, Lesmana CRA. Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia Pac J Clin Oncol 2023;19:263-74. [PMID: 35599455 DOI: 10.1111/ajco.13768] [Reference Citation Analysis]
3 Rao D, Lacroix R, Rooker A, Gomes T, Stunnenberg JA, Valenti M, Dimitriadis P, Lin CP, de Bruijn B, Krijgsman O, Ligtenberg MA, Peeper DS, Blank CU. MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance. Melanoma Res 2023;33:12-26. [PMID: 36545919 DOI: 10.1097/CMR.0000000000000863] [Reference Citation Analysis]
4 Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S. Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. Cancers 2023;15:852. [DOI: 10.3390/cancers15030852] [Reference Citation Analysis]
5 Friedman JS, Jun T, Rashidipour O, Huang KL, Ellis E, Kadaba P, Belani P, Nael K, Tsankova NM, Sebra R, Hormigo A. Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2023. [PMID: 36707424 DOI: 10.1007/s00262-023-03381-y] [Reference Citation Analysis]
6 wu L, Su J, Yang J, Gu L, Zhang R, Liu L, Lu H, Chen J. Use of Programmed Cell Death Protein 1 (PD-1) Inhibitor Therapy in HIV-infected Patients with Advanced Cancer:a single-center study from China.. [DOI: 10.21203/rs.3.rs-2474777/v1] [Reference Citation Analysis]
7 Ma X, Sun X, Xie F, Jian W, Wang Q, Xie Y, Li C, Kai Z. The influence of drug-eluting beads transarterial chemoembolization on serum levels of soluble programed cell death protein-1 in advanced hepatocellular carcinoma patients.. [DOI: 10.21203/rs.3.rs-2029599/v1] [Reference Citation Analysis]
8 Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Fucosylation of HLA-DRB1 regulates CD4(+) T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat Cancer 2023. [PMID: 36690875 DOI: 10.1038/s43018-022-00506-7] [Reference Citation Analysis]
9 Palanivelu L, Liu C, Lin L. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1038226] [Reference Citation Analysis]
10 Zhang F, Deng Y, Wang D, Wang S. Construction and Verification of the Molecular Subtype and a Novel Prognostic Signature Based on Inflammatory Response-Related Genes in Uveal Melanoma. JCM 2023;12:861. [DOI: 10.3390/jcm12030861] [Reference Citation Analysis]
11 Li SN, Wan X, Peng LB, Li YM, Li JH. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. BMC Health Serv Res 2023;23:49. [PMID: 36653848 DOI: 10.1186/s12913-023-09058-7] [Reference Citation Analysis]
12 Chen ZH, Zheng WH, Wu CF, Kou J, Yang XL, Lin L, Lv JW, Sun Y, Zhou GQ. Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response. BMC Med 2023;21:18. [PMID: 36647058 DOI: 10.1186/s12916-022-02697-3] [Reference Citation Analysis]
13 Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother 2023. [PMID: 36633661 DOI: 10.1007/s00262-022-03349-4] [Reference Citation Analysis]
14 Liu M, Li W, Ma X, Che Y, Wei B, Chen M, Zhong L, Zhao S, Chen A, Pang Y, Zeng J, Guo J. Gradient differences of immunotherapy efficacy in metastatic melanoma related to sunlight exposure pattern: A population-based study. Front Oncol 2022;12:1086664. [PMID: 36686834 DOI: 10.3389/fonc.2022.1086664] [Reference Citation Analysis]
15 Lee SM, Lee S, Cho HW, Min KJ, Hong JH, Song JY, Lee JK, Lee NW. Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors? Int J Mol Sci 2023;24. [PMID: 36674491 DOI: 10.3390/ijms24020974] [Reference Citation Analysis]
16 Hu R, Li Y, Guo Y, Li X, Du S, Liao M, Hou H, Sun H, Zhao S, Su J, Chen X, Yin M. BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway. Pharmacol Res 2023;187:106609. [PMID: 36516883 DOI: 10.1016/j.phrs.2022.106609] [Reference Citation Analysis]
17 Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
18 Blanchet K, Sebille JC, Frenard C, Lecerf P, Khammari A, Carlier T, Bodet-Milin C, Dréno B. The predictive power of FDG-PET imaging with regard to immunotherapy in real-life conditions in advanced melanoma: An exploratory study. J Eur Acad Dermatol Venereol 2022. [PMID: 35974443 DOI: 10.1111/jdv.18501] [Reference Citation Analysis]
19 Gaipl US, Grosu AL, Frey B, Rückert M, Schäfer H, Popp I. Strahlentherapie und Immuntherapie. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-46764-0_177-1] [Reference Citation Analysis]
20 Karizak AZ, Salmasi Z, Gheibihayat SM, Asadi M, Ghasemi Y, Tajbakhsh A, Savardashtaki A. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy. J Cancer Res Clin Oncol 2023;149:511-29. [PMID: 36342520 DOI: 10.1007/s00432-022-04452-w] [Reference Citation Analysis]
21 Singh G, Thakur N, Kumar U. RAS: Circuitry and therapeutic targeting. Cellular Signalling 2023;101:110505. [DOI: 10.1016/j.cellsig.2022.110505] [Reference Citation Analysis]
22 Medikonda R, Pant A, Lim M. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors. Adv Exp Med Biol 2023;1394:73-84. [PMID: 36587382 DOI: 10.1007/978-3-031-14732-6_5] [Reference Citation Analysis]
23 Coleman S, Xie M, Tarhini AA, Tan AC. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. Mol Carcinog 2023;62:77-89. [PMID: 35781709 DOI: 10.1002/mc.23442] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Razi S, Rezaei N. Introduction on Cancer Immunotherapy. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_180-1] [Reference Citation Analysis]
25 Shi Z, Liu X, Chen M, Zhang N, Guan H, Ye D. The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2022;101:e32393. [PMID: 36596018 DOI: 10.1097/MD.0000000000032393] [Reference Citation Analysis]
26 Nambara S, Sakaguchi Y, Tsuda Y, Kudou K, Kusumoto E, Yoshida R, Kusumoto T, Ikejiri K. Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab. Int Canc Conf J 2022. [DOI: 10.1007/s13691-022-00582-7] [Reference Citation Analysis]
27 Al-Saafeen BH, Al-Sbiei A, Bashir G, Mohamed YA, Masad RJ, Fernandez-Cabezudo MJ, Al-Ramadi BK. Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. Front Immunol 2022;13:1017780. [PMID: 36605208 DOI: 10.3389/fimmu.2022.1017780] [Reference Citation Analysis]
28 Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2022;4:579-97. [PMID: 36636451 DOI: 10.1016/j.jaccao.2022.09.004] [Reference Citation Analysis]
29 Borges R, Pelosine AM, de Souza ACS, Machado J Jr, Justo GZ, Gamarra LF, Marchi J. Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment. Materials (Basel) 2022;15. [PMID: 36556893 DOI: 10.3390/ma15249082] [Reference Citation Analysis]
30 Munhoz RR, Nader-Marta G, de Camargo VP, Queiroz MM, Cury-Martins J, Ricci H, de Mattos MR, de Menezes TAF, Machado GUC, Bertolli E, Barros M, de Souza CE, Franke F, Ferreira FO, Feher O, de Castro G Jr. A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma. Cancer 2022;128:4223-31. [PMID: 36274573 DOI: 10.1002/cncr.34463] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Wang H, Xu Y, Zuo F, Liu J, Yang J. Immune-based combination therapy for esophageal cancer. Front Immunol 2022;13:1020290. [PMID: 36591219 DOI: 10.3389/fimmu.2022.1020290] [Reference Citation Analysis]
32 Takahashi A, Namikawa K, Ogata D, Jinnai S, Nakano E, Yamazaki N. Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. The Journal of Dermatology 2022. [DOI: 10.1111/1346-8138.16669] [Reference Citation Analysis]
33 Kadota H, Yuge R, Shimizu D, Miyamoto R, Otani R, Hiyama Y, Takigawa H, Hayashi R, Urabe Y, Kitadai Y, Oka S, Tanaka S. Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. Cancers (Basel) 2022;14. [PMID: 36551634 DOI: 10.3390/cancers14246146] [Reference Citation Analysis]
34 Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer 2022;10. [PMID: 36600653 DOI: 10.1136/jitc-2022-005755] [Reference Citation Analysis]
35 Bukhari S, Henick BS, Winchester RJ, Lerrer S, Adam K, Gartshteyn Y, Maniar R, Lin Z, Khodadadi-Jamayran A, Tsirigos A, Salvatore MM, Lagos GG, Reiner SL, Dallos MC, Mathew M, Rizvi NA, Mor A. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep Med 2023;4:100868. [PMID: 36513074 DOI: 10.1016/j.xcrm.2022.100868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. BMC Cancer 2022;22:1292. [PMID: 36494792 DOI: 10.1186/s12885-022-10398-6] [Reference Citation Analysis]
37 Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 2022;310:121138. [DOI: 10.1016/j.lfs.2022.121138] [Reference Citation Analysis]
38 Bu MT, Chandrasekhar P, Ding L, Hugo W. The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. Pharmacol Ther 2022;240:108211. [PMID: 35577211 DOI: 10.1016/j.pharmthera.2022.108211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
39 Anestopoulos I, Kyriakou S, Tragkola V, Paraskevaidis I, Tzika E, Mitsiogianni M, Deligiorgi MV, Petrakis G, Trafalis DT, Botaitis S, Giatromanolaki A, Koukourakis MI, Franco R, Pappa A, Panayiotidis MI. Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. Pharmacol Ther 2022;240:108301. [PMID: 36283453 DOI: 10.1016/j.pharmthera.2022.108301] [Reference Citation Analysis]
40 Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, Finetti P, Krishnamurthy S, Phi LTH, Pearson T, Van Laere SJ, Burks JK, Cohen EN, Reuben JM, Yang F, Min H, Navin N, Trinh VN, Iwase T, Batra H, Shen Y, Zhang X, Tripathy D, Ueno NT. EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. Sci Adv 2022;8:eabn7983. [PMID: 36525493 DOI: 10.1126/sciadv.abn7983] [Reference Citation Analysis]
41 Xu C, Fang H, Gu Y, Yu K, Wang J, Lin C, Zhang H, Li H, He H, Liu H, Li R. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer. Cancer Sci 2022. [PMID: 35997524 DOI: 10.1111/cas.15537] [Reference Citation Analysis]
42 Gajón JA, Juarez-Flores A, De León Rodríguez SG, Aguilar Flores C, Mantilla A, Fuentes-Pananá EM, Bonifaz LC. Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy. Arch Med Res 2022;53:794-806. [PMID: 36460547 DOI: 10.1016/j.arcmed.2022.11.008] [Reference Citation Analysis]
43 Barros EM, Mcintosh SA, Savage KI. The DNA damage induced immune response: Implications for cancer therapy. DNA Repair 2022;120:103409. [DOI: 10.1016/j.dnarep.2022.103409] [Reference Citation Analysis]
44 Dezoteux F, Descamps V, Tétart F. Réactions cutanées aux inhibiteurs de checkpoint. Annales de Dermatologie et de Vénéréologie - FMC 2022. [DOI: 10.1016/j.fander.2022.06.009] [Reference Citation Analysis]
45 Loria R, Laquintana V, Scalera S, Fraioli R, Caprara V, Falcone I, Bazzichetto C, Di Martile M, Rosanò L, Del Bufalo D, Bossi G, Sperduti I, Terrenato I, Visca P, Soddu S, Milella M, Ciliberto G, Falcioni R, Ferraresi V, Bon G. SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. J Exp Clin Cancer Res 2022;41:148. [DOI: 10.1186/s13046-022-02354-w] [Reference Citation Analysis]
46 Mahdavi Gorabi A, Sadat Ravari M, Sanaei M, Davaran S, Kesharwani P, Sahebkar A. Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. International Immunopharmacology 2022;113:109300. [DOI: 10.1016/j.intimp.2022.109300] [Reference Citation Analysis]
47 Kahlon N, Doddi S, Yousif R, Najib S, Sheikh T, Abuhelwa Z, Burmeister C, Hamouda DM. Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. JAMA Netw Open 2022;5:e2245269. [PMID: 36472871 DOI: 10.1001/jamanetworkopen.2022.45269] [Reference Citation Analysis]
48 Long XY, Zhang S, Tang LS, Li X, Liu JY. Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature. World J Clin Cases 2022; 10(33): 12305-12312 [DOI: 10.12998/wjcc.v10.i33.12305] [Reference Citation Analysis]
49 Sun Z, Jiang H, Yan T, Deng G, Chen Q. Identification of Immunogenic Cell Death-Related Signature for Glioma to Predict Survival and Response to Immunotherapy. Cancers (Basel) 2022;14. [PMID: 36428756 DOI: 10.3390/cancers14225665] [Reference Citation Analysis]
50 Hamano H, Miyata K, Hara T, Sakaguchi S, Oura M, Niimura T, Aizawa F, Yagi K, Okada N, Miki H, Goda M, Ishizawa-izawa Y, Zamami Y, Yanagawa H, Ishizawa K. Multiple Adverse Events of anti-PD1/PDL1 Therapy: A Case- control Study using a Japanese Prescription-diagnostics Database.. [DOI: 10.21203/rs.3.rs-2268880/v1] [Reference Citation Analysis]
51 E. Omar N, M. Afifi H, O. Sahal A, Mekkawi R, Elewa H. The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects. Immune Checkpoint Inhibitors - New Insights and Recent Progress [Working Title] 2022. [DOI: 10.5772/intechopen.107833] [Reference Citation Analysis]
52 Damaskos C, Garmpis N, Dimitroulis D, Garmpi A, Psilopatis I, Sarantis P, Koustas E, Kanavidis P, Prevezanos D, Kouraklis G, Karamouzis MV, Marinos G, Kontzoglou K, Antoniou EA. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review. Int J Mol Sci 2022;23. [PMID: 36430594 DOI: 10.3390/ijms232214117] [Reference Citation Analysis]
53 Sánchez-molina S, Figuerola-bou E, Sánchez-margalet V, de la Cruz-merino L, Mora J, de Álava Casado E, García-domínguez DJ, Hontecillas-prieto L. Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies. Cancers 2022;14:5473. [DOI: 10.3390/cancers14215473] [Reference Citation Analysis]
54 Munari E, Quatrini L, Ciancaglini C, Eccher A, Bogina G, Moretta L, Mariotti FR. Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells. Semin Immunol 2022;61-64:101660. [PMID: 36370672 DOI: 10.1016/j.smim.2022.101660] [Reference Citation Analysis]
55 Corrie P, Meyer N, Berardi R, Guidoboni M, Schlueter M, Kolovos S, Macabeo B, Trouiller JB, Laramée P. Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Cancer Treat Rev 2022;110:102463. [PMID: 36099854 DOI: 10.1016/j.ctrv.2022.102463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Shi S, Huang J, Kuang Y, Ruan S. Stability and Hopf bifurcation of a tumor–immune system interaction model with an immune checkpoint inhibitor. Communications in Nonlinear Science and Numerical Simulation 2022. [DOI: 10.1016/j.cnsns.2022.106996] [Reference Citation Analysis]
57 Anderson TS, Wooster AL, Piersall SL, Okpalanwaka IF, Lowe DB. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Semin Cancer Biol 2022;86:981-96. [PMID: 35149179 DOI: 10.1016/j.semcancer.2022.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
58 Miao K, Zhang L. Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. Cancer Pathogenesis and Therapy 2022. [DOI: 10.1016/j.cpt.2022.11.003] [Reference Citation Analysis]
59 Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, Kähler KC, French LE, Heinzerling L. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life. Eur J Cancer 2022;176:88-99. [PMID: 36198246 DOI: 10.1016/j.ejca.2022.08.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Gupta S, Shukla S. Limitations of Immunotherapy in Cancer. Cureus 2022. [DOI: 10.7759/cureus.30856] [Reference Citation Analysis]
61 Iscaro A, H.n. Howard F, Yang Z, Jenkins F, Muthana M. Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer. Liposomes - Recent Advances, New Perspectives and Applications [Working Title] 2022. [DOI: 10.5772/intechopen.108282] [Reference Citation Analysis]
62 Zhong W, Shen Z, Wu Y, Mao X, Kong J, Wu W. Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1014981] [Reference Citation Analysis]
63 Qian MF, Betancourt NJ, Pineda A, Maloney NJ, Nguyen KA, Reddy SA, Hall ET, Swetter SM, Zaba LC. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. The Oncologist 2022. [DOI: 10.1093/oncolo/oyac219] [Reference Citation Analysis]
64 Zubair AS, Roy B, Baehring JM, Nowak RJ. Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. Cureus 2022. [DOI: 10.7759/cureus.30638] [Reference Citation Analysis]
65 Kakish HH, Ahmed FA, Elshami M, Loftus AW, Hoehn RS, Ammori JB, Ocuin LM, Winter JM, Bordeaux JS, Mangla A, Rothermel LD. Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms? Cancers 2022;14:5184. [DOI: 10.3390/cancers14215184] [Reference Citation Analysis]
66 Hendricks WPD, Sekulic A, Bryce AH, Murtaza M, Ramos P, Lang JD, Whitsett TG, Mcdaniel TK, Rockne RC, Banovich N, Trent JM. Cancer Genomics and Evolution. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm007.pub2] [Reference Citation Analysis]
67 Lau E, Lester D, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson D, Frederick D, Sharova T, White M, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-macias A, Mercurio M, Watson G, Chen P, Mccarthy S, Moran C, Messina J, Thomas K, Darville L, Izuma V, Koomen J, Pilon-thomas S, Ruffell B, Luca V, Haltiwanger RS, Wang X, Wargo J, Boland G. Fucosylation of HLA-DRB1 regulates CD4+T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.. [DOI: 10.21203/rs.3.rs-2023267/v1] [Reference Citation Analysis]
68 He Y, Zhang S, Zhang X, Zhang Y, Xie B, Zhang J, Long W, Liu Q. A prognostic cuproptosis gene signature predicts immune function and chemotherapy response in gliomas.. [DOI: 10.21203/rs.3.rs-2155356/v1] [Reference Citation Analysis]
69 Bayat M, Doroudinia A, Karam MB, Mehrian P. FDG PET/CT in Immune-Related Arthritis in a Patient Treated With Nivolumab. Clin Nucl Med 2022. [PMID: 36252811 DOI: 10.1097/RLU.0000000000004429] [Reference Citation Analysis]
70 Pan J, Liu Y, Guo X, Bai Z, Levi Sandri GB, Méndez-Sánchez N, Qi X. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Expert Opin Drug Saf 2022. [PMID: 36214583 DOI: 10.1080/14740338.2022.2134854] [Reference Citation Analysis]
71 Zhou Y, Hu F, Cui Y, Wu H, Hu S, Wei W. Bibliometric analysis of research on immunogenic cell death in cancer. Front Pharmacol 2022;13:1029020. [DOI: 10.3389/fphar.2022.1029020] [Reference Citation Analysis]
72 Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Gavilá J, López-González A, Cejalvo JM, Izarzugaza Y, Amillano K, Corbacho JG, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesía R, Cervantes A, Tabernero J. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future Oncol 2022. [PMID: 36200668 DOI: 10.2217/fon-2022-0660] [Reference Citation Analysis]
73 Sezen D, Barsoumian HB, He K, Hu Y, Wang Q, Abana CO, Puebla-osorio N, Hsu EY, Wasley M, Masrorpour F, Wang J, Cortez MA, Welsh JW. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol 2022;13:984318. [DOI: 10.3389/fimmu.2022.984318] [Reference Citation Analysis]
74 Niu Z, Jin R, Zhang Y, Li H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduct Target Ther 2022;7:353. [PMID: 36198685 DOI: 10.1038/s41392-022-01200-x] [Reference Citation Analysis]
75 Lazaroff J, Bolotin D. Targeted Therapy and Immunotherapy in Melanoma. Dermatologic Clinics 2022. [DOI: 10.1016/j.det.2022.07.007] [Reference Citation Analysis]
76 Wu C, Chu C, Wang F, Yang H, Tseng W, Chang C, Chang C. A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease. Cell Biosci 2022;12:162. [DOI: 10.1186/s13578-022-00897-1] [Reference Citation Analysis]
77 Ferraz CAA, Grougnet R, Nicolau E, Picot L, de Oliveira Junior RG. Carotenoids from Marine Microalgae as Antimelanoma Agents. Marine Drugs 2022;20:618. [DOI: 10.3390/md20100618] [Reference Citation Analysis]
78 Azuma T, Kano M, Iwata S, Honda S, Miyoshi Y, Nishiguchi J. Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. PLoS ONE 2022;17:e0274451. [DOI: 10.1371/journal.pone.0274451] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Chera A, Stancu AL, Bucur O. Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol 2022;13:1010279. [DOI: 10.3389/fendo.2022.1010279] [Reference Citation Analysis]
80 Rivera-grana E, M. Llop S. Immunotherapy-Associated Uveitis. Eye Diseases - Recent Advances, New Perspectives and Therapeutic Options [Working Title] 2022. [DOI: 10.5772/intechopen.106442] [Reference Citation Analysis]
81 Irabor OC, Nelson N, Shah Y, Niazi MK, Poiset S, Storozynsky E, Singla DK, Hooper DC, Lu B. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Front Oncol 2022;12:940127. [DOI: 10.3389/fonc.2022.940127] [Reference Citation Analysis]
82 Ji H, Liu Z, Wang F, Sun H, Wang N, Liu Y, Hu S, You C. Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction. Front Immunol 2022;13:941556. [DOI: 10.3389/fimmu.2022.941556] [Reference Citation Analysis]
83 Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Front Immunol 2022;13:982026. [DOI: 10.3389/fimmu.2022.982026] [Reference Citation Analysis]
84 Goh LY, Limbachia K, Moonim M, Morley AMS. Primary lacrimal sac melanoma: a case report describing the novel use of fine needle aspiration cytology (FNAC) for diagnosis, together with literature review and immunotherapy treatment update. Orbit 2022;:1-10. [PMID: 36069101 DOI: 10.1080/01676830.2022.2119264] [Reference Citation Analysis]
85 Śledzińska P, Bebyn M, Furtak J, Koper A, Koper K. Current and promising treatment strategies in glioma. Rev Neurosci 2022. [PMID: 36062548 DOI: 10.1515/revneuro-2022-0060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Zhang T, Wang Y, Shi C, Liu X, Lv S, Wang X, Li W. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Front Pharmacol 2022;13:955701. [DOI: 10.3389/fphar.2022.955701] [Reference Citation Analysis]
87 Pradeep J, Win TT, Aye SN, Sreeramareddy CT. Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy. J Cancer 2022;13:3091-102. [PMID: 36046644 DOI: 10.7150/jca.72210] [Reference Citation Analysis]
88 Almohideb M. Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis. Medicine 2022;101:e29390. [DOI: 10.1097/md.0000000000029390] [Reference Citation Analysis]
89 Indini A, Fiorilla I, Ponzone L, Calautti E, Audrito V. NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. IJMS 2022;23:9985. [DOI: 10.3390/ijms23179985] [Reference Citation Analysis]
90 Sachpekidis C, Hassel JC, Dimitrakopoulou-strauss A. Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03453-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Shi Z, Tu J, Ying Y, Diao Y, Zhang P, Liao S, Xiong Z, Huang S. CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance. Cancers 2022;14:4251. [DOI: 10.3390/cancers14174251] [Reference Citation Analysis]
92 Yigit A, Kuscu B, Kirik A, Ozcaglayan R, Afsar CU. New Biomarkers and Immunotherapy Decision. Biomarkers in Medicine 2022. [DOI: 10.2174/9789815040463122010003] [Reference Citation Analysis]
93 Basak EA, Vermeer NS, de Joode K, Hurkmans DP, Velthuis DEM, Oomen-de Hoop E, Schreurs MWJ, Bins S, Koolen SLW, Debets R, van der Veldt AAM, Aerts JGJV, Joosse A, Mathijssen RHJ. Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. Eur J Cancer 2022;174:113-20. [PMID: 35988409 DOI: 10.1016/j.ejca.2022.07.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Peterson C, Denlinger N, Yang Y. Recent Advances and Challenges in Cancer Immunotherapy. Cancers 2022;14:3972. [DOI: 10.3390/cancers14163972] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Chikhaoui A, Jones M, Režen T, Ben Ahmed M, Naouali C, Komel R, Zghal M, Boubaker S, Abdelhak S, Yacoub-Youssef H. Inflammatory landscape in Xeroderma pigmentosum patients with cutaneous melanoma. Sci Rep 2022;12:13854. [PMID: 35974070 DOI: 10.1038/s41598-022-17928-z] [Reference Citation Analysis]
96 Shi D, Zhong W, Liu D, Sun X, Hao S, Yang Y, Ao L, Zhou J, Xia Y, Zhou Y, Yu H, Xia H. Computational identification of immune-related lncRNA signature for predicting the prognosis and immune landscape of human glioblastoma multiforme. Front Immunol 2022;13:932938. [DOI: 10.3389/fimmu.2022.932938] [Reference Citation Analysis]
97 Samaran Q, Samaran R, Ferreira E, Haddad N, Fottorino A, Maillard H, Dreno B, Meyer N, Azria D, Maubec E, Gaudy-Marqueste C, Molinari N, Stoebner PE, Dereure O. Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey. J Cancer Res Clin Oncol 2022. [PMID: 35962286 DOI: 10.1007/s00432-022-04246-0] [Reference Citation Analysis]
98 Niu D, Chen Y, Mi H, Mo Z, Pang G. The epiphany derived from T-cell–inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. Front Genet 2022;13:974416. [DOI: 10.3389/fgene.2022.974416] [Reference Citation Analysis]
99 van Breeschoten J, Ismail RK, Wouters MW, Hilarius DL, de Wreede LC, Haanen JB, Blank CU, Aarts MJ, van den Berkmortel FW, de Groot JWB, Hospers GA, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MA, van der Veldt AA, Vreugdenhil G, Boers-sonderen MJ, Suijkerbuijk KP, van den Eertwegh AJ. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study. JCO Oncology Practice 2022. [DOI: 10.1200/op.22.00061] [Reference Citation Analysis]
100 Gao J, Miao J, Sun H, Fu X, Zhang P, Chen Z, Zhu P. TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice. Front Immunol 2022;13:955812. [DOI: 10.3389/fimmu.2022.955812] [Reference Citation Analysis]
101 Lin EP, Hsu CY, Berry L, Bunn P, Shyr Y. Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses. JAMA Netw Open 2022;5:e2227211. [PMID: 35976648 DOI: 10.1001/jamanetworkopen.2022.27211] [Reference Citation Analysis]
102 Lamba N, Ott PA, Iorgulescu JB. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era. JAMA Netw Open 2022;5:e2225459. [PMID: 36006646 DOI: 10.1001/jamanetworkopen.2022.25459] [Reference Citation Analysis]
103 Ritterhouse LL, Gogakos T. Molecular Biomarkers of Response to Cancer Immunotherapy. Clinics in Laboratory Medicine 2022. [DOI: 10.1016/j.cll.2022.05.004] [Reference Citation Analysis]
104 Steiger HJ, Vollmer K, Rogers S, Schwyzer L. State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain. Neurosurg Rev 2022. [PMID: 35902427 DOI: 10.1007/s10143-022-01839-8] [Reference Citation Analysis]
105 Righini M, Mollica V, Rizzo A, La Manna G, Massari F. Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. JCM 2022;11:4373. [DOI: 10.3390/jcm11154373] [Reference Citation Analysis]
106 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
107 Kim HS, Kim CG, Hong JY, Kim IH, Kang B, Jung S, Kim C, Shin SJ, Choi HJ, Cheon J, Chon HJ, Lim HY. The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:17588359221113266. [PMID: 35860833 DOI: 10.1177/17588359221113266] [Reference Citation Analysis]
108 Wu C, Qin C, Long W, Wang X, Xiao K, Liu Q. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. J Big Data 2022;9:92. [PMID: 35855914 DOI: 10.1186/s40537-022-00643-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Li Y, Liang X, Li H, Yang T, Guo S, Chen X. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Front Pharmacol 2022;13:906956. [DOI: 10.3389/fphar.2022.906956] [Reference Citation Analysis]
110 Tian Y, Zhang C, Dang Q, Wang K, Liu Q, Liu H, Shang H, Zhao J, Xu Y, Wu T, Liu W, Yang X, Safi M, Wu YS. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/4976032] [Reference Citation Analysis]
111 Spagnolo P, Chaudhuri N, Bernardinello N, Karampitsakos T, Sampsonas F, Tzouvelekis A. Pulmonary adverse events following immune checkpoint inhibitors. Curr Opin Pulm Med 2022. [PMID: 35838354 DOI: 10.1097/MCP.0000000000000895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 van Pul KM, Notohardjo JCL, Fransen MF, Koster BD, Stam AGM, Chondronasiou D, Lougheed SM, Bakker J, Kandiah V, van den Tol MP, Jooss K, Vuylsteke RJCLM, van den Eertwegh AJM, de Gruijl TD. Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic T reg reduction and effector T cell activation. Sci Immunol 2022;7:eabn8097. [DOI: 10.1126/sciimmunol.abn8097] [Reference Citation Analysis]
113 Ohanna M, Biber P, Deckert M. Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis. Cancers 2022;14:3371. [DOI: 10.3390/cancers14143371] [Reference Citation Analysis]
114 Shui IM, Liu XQ, Zhao Q, Kim ST, Sun Y, Yearley JH, Choudhury T, Webber AL, Krepler C, Cristescu R, Lee J. Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. J Immunother Cancer 2022;10:e004879. [PMID: 35793874 DOI: 10.1136/jitc-2022-004879] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Lau S, Klaase L, Vink M, Dumas J, Bezemer K, van Krimpen A, van der Breggen R, Wismans L, Doukas M, de Koning W, Stubbs A, Mustafa D, Vroman H, Stadhouders R, Nunes J, Stingl C, de Miranda N, Luider T, van der Burg S, Aerts J, van Eijck C. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study. European Journal of Cancer 2022;169:20-31. [DOI: 10.1016/j.ejca.2022.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Hercun J, Vincent C, Bilodeau M, Lapierre P. Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. Front Immunol 2022;13:907591. [DOI: 10.3389/fimmu.2022.907591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Dong M, Yu T, Zhang Z, Zhang J, Wang R, Tse G, Liu T, Zhong L. ICIs-Related Cardiotoxicity in Different Types of Cancer. JCDD 2022;9:203. [DOI: 10.3390/jcdd9070203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
118 Imenez Silva PH, Câmara NO, Wagner CA. Role of proton-activated G protein-coupled receptors in pathophysiology. Am J Physiol Cell Physiol 2022. [PMID: 35759438 DOI: 10.1152/ajpcell.00114.2022] [Reference Citation Analysis]
119 Oprea A, Benas A, Havasi A, Gorzo A, Spinu S, Sur D, Burz C. Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report. Cureus 2022. [DOI: 10.7759/cureus.26359] [Reference Citation Analysis]
120 Kato T, Okada R, Furusawa A, Wakiyama H, Furumoto H, Fukushima H, Okuyama S, Choyke PL, Kobayashi H. Comparison of the Effectiveness of IgG Antibody versus F(ab')2 Antibody Fragment in CTLA4-Targeted Near-Infrared Photoimmunotherapy. Mol Pharm 2022. [PMID: 35759343 DOI: 10.1021/acs.molpharmaceut.2c00242] [Reference Citation Analysis]
121 Jinga D, Jinga M. Immunotherapy of Metastatic Melanoma. Melanoma - Standard of Care, Challenges, and Updates in Clinical Research [Working Title] 2022. [DOI: 10.5772/intechopen.105585] [Reference Citation Analysis]
122 Takahashi Y, Nagaya T, Iwaya Y, Okamura T, Hirayama A, Iwaya M, Uehara T, Umemura T. CD8(+) Lymphocyte Infiltration Is a Specific Feature of Colitis Induced by Immune Checkpoint Inhibitors. Dig Dis Sci 2022. [PMID: 35748996 DOI: 10.1007/s10620-022-07598-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Lau SP, van 't Land FR, van der Burg SH, Homs MYV, Lolkema MP, Aerts JGJV, van Eijck CHJ. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial). BMJ Open 2022;12:e060431. [PMID: 35710239 DOI: 10.1136/bmjopen-2021-060431] [Reference Citation Analysis]
124 Wang J, Ling S, Ni J, Wan Y. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma. BMC Cancer 2022;22:638. [PMID: 35681134 DOI: 10.1186/s12885-022-09662-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Wu Q, Luo S, Xie X. Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75? J Immunother 2022. [PMID: 35674663 DOI: 10.1097/CJI.0000000000000426] [Reference Citation Analysis]
126 Villani A, Potestio L, Fabbrocini G, Troncone G, Malapelle U, Scalvenzi M. The Treatment of Advanced Melanoma: Therapeutic Update. Int J Mol Sci 2022;23:6388. [PMID: 35742834 DOI: 10.3390/ijms23126388] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
127 Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. Br J Cancer. [DOI: 10.1038/s41416-022-01864-w] [Reference Citation Analysis]
128 Landström FJ, Jakobsson FE, Kristiansson SJ. Successful electrochemotherapy treatment of a large bleeding lymph node melanoma metastasis. Melanoma Manag 2022;9:MMT61. [PMID: 35813184 DOI: 10.2217/mmt-2021-0006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Sanmamed MF, Berraondo P, Rodriguez-ruiz ME, Melero I. Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat Cancer 2022;3:665-680. [DOI: 10.1038/s43018-022-00401-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Liu Y, Huang T, Shen L, Wu Y, Chen S, Fan W. Research progress on anti-tumor immune effect of cryoablation. Chin J Acad Radiol 2022;5:74-81. [DOI: 10.1007/s42058-022-00092-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Qayoom H, Mehraj U, Aisha S, Sofi S, Ahmad Mir M. Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing. Drug Repurposing - Molecular Aspects and Therapeutic Applications 2022. [DOI: 10.5772/intechopen.100183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
132 Uhara H, Tsuchida T, Kiyohara Y, Akamatsu A, Sakamoto T, Yamazaki N. Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance. J Dermatol 2022. [PMID: 35607248 DOI: 10.1111/1346-8138.16432] [Reference Citation Analysis]
133 Kothari G. Role of radiomics in predicting immunotherapy response. J Med Imaging Radiat Oncol 2022. [PMID: 35581928 DOI: 10.1111/1754-9485.13426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
134 Navani V, Graves MC, Mandaliya H, Hong M, van der Westhuizen A, Martin J, Bowden NA. Melanoma: An immunotherapy journey from bench to bedside. Cancer Treat Res 2022;183:49-89. [PMID: 35551656 DOI: 10.1007/978-3-030-96376-7_2] [Reference Citation Analysis]
135 Nomura M. Association of the gut microbiome with cancer immunotherapy. Int J Clin Oncol 2022. [PMID: 35568746 DOI: 10.1007/s10147-022-02180-2] [Reference Citation Analysis]
136 Stahlie EHA, Mulder EEAP, Reijers S, Balduzzi S, Zuur CL, Klop WMC, van der Hiel B, Van de Wiel BA, Wouters MWJM, Schrage YM, van Houdt WJ, Grunhagen DJ, van Akkooi ACJ. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2022;:103705. [PMID: 35569723 DOI: 10.1016/j.critrevonc.2022.103705] [Reference Citation Analysis]
137 Glass EB, Hoover AA, Bullock KK, Madden MZ, Reinfeld BI, Harris W, Parker D, Hufnagel DH, Crispens MA, Khabele D, Rathmell WK, Rathmell JC, Wilson AJ, Giorgio TD, Yull FE. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. BMC Cancer 2022;22:497. [PMID: 35513776 DOI: 10.1186/s12885-022-09612-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
138 Xavier CB, Lopes CDH, Harada G, Peres EDB, Katz A, Jardim DL. Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. Translational Oncology 2022;19:101383. [DOI: 10.1016/j.tranon.2022.101383] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Upadhyaya SN, Knackstedt RW, Ko JS, Gastman BR. The Use and Technique of Sentinel Node Biopsy for Skin Cancer. Plast Reconstr Surg 2022;149:995e-1008e. [PMID: 35472052 DOI: 10.1097/PRS.0000000000009010] [Reference Citation Analysis]
140 In GK, Nallagangula A, Choi JS, Tachiki L, Blackburn MJ, Capone S, Bollin KB, Reuben DY, Shirai K, Zhang-Nunes S, Ragab O, Terando A, Hu JC, Lee H, Bhatia S, Chandra S, Lutzky J, Gibney GT. Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. J Immunother Cancer 2022;10:e004839. [PMID: 35545318 DOI: 10.1136/jitc-2022-004839] [Reference Citation Analysis]
141 Hou Y, Liu Y, Tang C, Tan Y, Zheng X, Deng Y, He N, Li S. Recent advance in nanomaterials for cancer immunotherapy. Chemical Engineering Journal 2022;435:134145. [DOI: 10.1016/j.cej.2021.134145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
142 Holmberg C, Ny L, Hieken TJ, Block MS, Carr MJ, Sondak VK, Örtenwall C, Katsarelias D, Dimitriou F, Menzies AM, Saw RP, Rogiers A, Straker RJ, Karakousis G, Applewaite R, Pallan L, Han D, Vetto JT, Gyorki DE, Tie EN, Vitale MG, Ascierto PA, Dummer R, Cohen J, Hui JY, Schachter J, Asher N, Helgadottir H, Chai H, Kroon H, Coventry B, Rothermel LD, Sun J, Carlino MS, Duncan Z, Broman K, Weber J, Lee AY, Berman RS, Teras J, Ollila DW, Long GV, Zager JS, van Akkooi A, Olofsson Bagge R. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.03.041] [Reference Citation Analysis]
143 Aroldi F, Middleton MR. Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. Am J Clin Dermatol 2022;23:331-8. [PMID: 35359259 DOI: 10.1007/s40257-022-00681-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
144 Gorris MAJ, van der Woude LL, Kroeze LI, Bol K, Verrijp K, Amir AL, Meek J, Textor J, Figdor CG, de Vries IJM. Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. J Immunother Cancer 2022;10:e004329. [PMID: 35550553 DOI: 10.1136/jitc-2021-004329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Kumar P, Brazel D, DeRogatis J, Valerin JBG, Whiteson K, Chow WA, Tinoco R, Moyers JT. The cure from within? a review of the microbiome and diet in melanoma. Cancer Metastasis Rev 2022. [PMID: 35474500 DOI: 10.1007/s10555-022-10029-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Wu HL, Gong Y, Ji P, Xie YF, Jiang YZ, Liu GY. Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. J Hematol Oncol 2022;15:45. [PMID: 35477416 DOI: 10.1186/s13045-022-01263-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
147 Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA. Targeting the gut and tumor microbiota in cancer. Nat Med 2022;28:690-703. [PMID: 35440726 DOI: 10.1038/s41591-022-01779-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
148 Nakano R, Shiomi H, Fujiwara A, Yoshihara K, Yoshioka R, Kawata S, Ota S, Yuri Y, Takashima T, Aizawa N, Ikeda N, Nishimura T, Enomoto H, Iijima H. Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. Healthcare 2022;10:763. [DOI: 10.3390/healthcare10050763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Bruijnen CP, Koldenhof JJ, Verheijden RJ, van den Bos F, Emmelot-Vonk MH, Witteveen PO, Suijkerbuijk KPM. Frailty and checkpoint inhibitor toxicity in older patients with melanoma. Cancer 2022. [PMID: 35439334 DOI: 10.1002/cncr.34230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Policheni AN, Teh CE, Robbins A, Tuzlak S, Strasser A, Gray DHD. PD-1 cooperates with AIRE-mediated tolerance to prevent lethal autoimmune disease. Proc Natl Acad Sci U S A 2022;119:e2120149119. [PMID: 35394861 DOI: 10.1073/pnas.2120149119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Fusco R, Simonetti I, Ianniello S, Villanacci A, Grassi F, Dell’aversana F, Grassi R, Cozzi D, Bicci E, Palumbo P, Borgheresi A, Giovagnoni A, Miele V, Barile A, Granata V. Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic. JPM 2022;12:624. [DOI: 10.3390/jpm12040624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Chen X, Li Z, Wang X, Zhou J, Wei Q, Jiang R. Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy. Support Care Cancer. [DOI: 10.1007/s00520-022-07005-6] [Reference Citation Analysis]
153 Dhanyamraju PK, Rotimi S, Bhattacharya P, Patel TN. Revisiting the melanomagenic pathways and current therapeutic approaches. Mol Biol Rep. [DOI: 10.1007/s11033-022-07412-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Wang H, Zhou F, Zhao C, Cheng L, Zhou C, Qiao M, Li X, Chen X. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy. Front Immunol 2022;13:840313. [PMID: 35222434 DOI: 10.3389/fimmu.2022.840313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
155 Plazy C, Hannani D, Gobbini E. Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review. Curr Oncol Rep 2022. [PMID: 35389138 DOI: 10.1007/s11912-022-01241-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
156 Zheng J, Cui T, Gao Y, Li T. Retrospective analysis of immune-related adverse events of the immune checkpoint inhibitors of PD-1/PD-l1 in the Fujian provincial hospital. Eur J Inflamm 2022;20:1721727X2210915. [DOI: 10.1177/1721727x221091540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Vargas Pivato de Almeida D. Neurological Toxic Effects Associated With Treatment With Immune Checkpoint Inhibitors-Are We Really Safer Now? JAMA Netw Open 2022;5:e227731. [PMID: 35438762 DOI: 10.1001/jamanetworkopen.2022.7731] [Reference Citation Analysis]
158 Ernst M, Giubellino A. The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. Biomedicines 2022;10:822. [DOI: 10.3390/biomedicines10040822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
159 Sasaki H, Kato J, Horimoto K, Sato S, Hosokawa Y, Handa T, Kobayashi E, Furudate K, Sigyo H, Tsuchiya T, Someya M, Uhara H. Delayed-onset abscopal effect after palliative radiotherapy for acral melanoma treated with anti-PD-1 therapy. J Dermatol 2022. [PMID: 35352846 DOI: 10.1111/1346-8138.16380] [Reference Citation Analysis]
160 Fu XL, Feng LP, Yu HR, Du L, Song YP, Chen HL. Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials. Melanoma Res 2022. [PMID: 35377859 DOI: 10.1097/CMR.0000000000000812] [Reference Citation Analysis]
161 Jansen Y, van der Veldt AAM, Awada G, Neyns B. Anti-PD-1: When to Stop Treatment. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01264-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Kaushik I, Ramachandran S, Zabel C, Gaikwad S, Srivastava SK. The evolutionary legacy of immune checkpoint inhibitors. Semin Cancer Biol 2022:S1044-579X(22)00076-1. [PMID: 35341912 DOI: 10.1016/j.semcancer.2022.03.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
163 Olsen TA, Zhuang TZ, Caulfield S, Martini DJ, Brown JT, Carthon BC, Kucuk O, Harris W, Bilen MA, Nazha B. Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Front Endocrinol 2022;13:779915. [DOI: 10.3389/fendo.2022.779915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
164 Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol 2022. [PMID: 35298698 DOI: 10.1007/s00280-022-04414-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Xiaochen M, Xiangyang S, Fubo X, Wencheng J, Qingliang W, Yang X, Caixia L, Kai Z. The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand-1 in advanced hepatocellular carcinoma patients. Asia Pac J Clin Oncol 2022. [PMID: 35289092 DOI: 10.1111/ajco.13687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Liu J, Geng R, Ni S, Cai L, Yang S, Shao F, Bai J. Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC. Mol Ther Nucleic Acids 2022;27:1036-55. [PMID: 35228898 DOI: 10.1016/j.omtn.2022.01.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
167 Loo K, Smithy JW, Postow MA, Betof Warner A. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Front Immunol 2021;12:810388. [PMID: 35087529 DOI: 10.3389/fimmu.2021.810388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Higgins MJ, Alipour R, Pope K, Ung KA, Kok DL, Chua MS. QUAD SHOT radiotherapy and doublet immunotherapy in the management of anal mucosal melanoma: A case series of efficacy and toxicity of a novel treatment approach and a review of the literature. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.03.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Guo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, Rothlin CV, Kluger HM, Desir GV. Inhibition of renalase drives tumour rejection by promoting T cell activation. Eur J Cancer 2022;165:81-96. [PMID: 35219026 DOI: 10.1016/j.ejca.2022.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Queiroz MM, Bertolli E, Belfort FA, Munhoz RR. Management of In-Transit Metastases. Curr Oncol Rep 2022. [PMID: 35192119 DOI: 10.1007/s11912-022-01216-0] [Reference Citation Analysis]
171 Maniar A, Haslam A, Prasad V. Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. Eur J Cancer 2022;164:95-104. [PMID: 35182927 DOI: 10.1016/j.ejca.2022.01.006] [Reference Citation Analysis]
172 Hao Y, Cook MC. Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. Front Immunol 2021;12:806043. [PMID: 35154081 DOI: 10.3389/fimmu.2021.806043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
173 Allouchery M, Beuvon C, Pérault-Pochat MC, Roblot P, Puyade M, Martin M. Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers (Basel) 2022;14:955. [PMID: 35205703 DOI: 10.3390/cancers14040955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
174 Konwar M, Bose D, Maurya M, Ravi R. A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis. J Oncol Pharm Pract 2022;:10781552221074315. [PMID: 35147454 DOI: 10.1177/10781552221074315] [Reference Citation Analysis]
175 Sabbatino F, Liguori L, Pepe S, Ferrone S. Immune checkpoint inhibitors for the treatment of melanoma. Expert Opin Biol Ther 2022. [PMID: 35130816 DOI: 10.1080/14712598.2022.2038132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Burke AM, Carrasquilla M, Jean WC, Collins BT, Anaizi AN, Atkins MB, Gibney GT, Collins SP. Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy. Front Oncol 2021;11:794615. [PMID: 35096594 DOI: 10.3389/fonc.2021.794615] [Reference Citation Analysis]
177 Zhang F, Deng Y, Wang D, Wang S. Construction and validation of a pyroptosis-related gene signature associated with the tumor microenvironment in uveal melanoma. Sci Rep 2022;12:1640. [PMID: 35102195 DOI: 10.1038/s41598-022-05599-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Mouratidis PXE, Ter Haar G. Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. Cancers (Basel) 2022;14:638. [PMID: 35158903 DOI: 10.3390/cancers14030638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Friedman CF, Spencer C, Cabanski CR, Panageas KS, Wells DK, Ribas A, Tawbi H, Tsai K, Postow M, Shoushtari A, Chapman P, Karakunnel J, Bucktrout S, Gherardini P, Hollmann TJ, Chen RO, Callahan M, Lavallee T, Ibrahim R, Wolchok J. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer 2022;10:e003853. [DOI: 10.1136/jitc-2021-003853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
180 Tolstrup LK, Pappot H, Bastholt L, Möller S, Dieperink KB. Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial. J Patient Rep Outcomes 2022;6. [DOI: 10.1186/s41687-022-00414-5] [Reference Citation Analysis]
181 Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022;15:6. [PMID: 35033167 DOI: 10.1186/s13045-021-01182-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
182 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
183 Schlauch D, Fu X, Jones SF, Burris HA 3rd, Spigel DR, Reeves J, McKenzie AJ. Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precis Oncol 2021;5:1625-38. [PMID: 34994650 DOI: 10.1200/PO.21.00008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
184 Sano A, Sohda M, Nakazawa N, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sakai M, Ogawa H, Shirabe K, Saeki H. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer 2022;22:22. [PMID: 34980017 DOI: 10.1186/s12885-021-09118-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Panuciak K, Margas M, Makowska K, Lejman M. Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. Cells 2022;11:139. [PMID: 35011701 DOI: 10.3390/cells11010139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
186 Zhang HC, Wang LS, Miller E. Hepatobiliary and Pancreatic Adverse Events. Adv Exp Med Biol 2021;1342:339-55. [PMID: 34972973 DOI: 10.1007/978-3-030-79308-1_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Lee C, Seetharamu N. The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_63] [Reference Citation Analysis]
188 Schilling B, Gesierich A. Melanome der Haut und Schleimhaut. Medikamentöse Tumortherapie von Kopf-Hals-Tumoren 2022. [DOI: 10.1007/978-3-662-62808-9_8] [Reference Citation Analysis]
189 Yu Y, Wang W, Qin Z, Li H, Liu Q, Ma H, Sun H, Bauer TL, Pimiento JM, Gabriel E, Birdas T, Li Y, Xing W. A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy. Ann Transl Med 2022;10:102. [PMID: 35282099 DOI: 10.21037/atm-22-78] [Reference Citation Analysis]
190 Rossi CR, Sommariva A. Melanoma. Plastic Surgery - Principles and Practice 2022. [DOI: 10.1016/b978-0-323-65381-7.00008-3] [Reference Citation Analysis]
191 Darbeheshti F. The Immunogenetics of Melanoma. The Immunogenetics of Dermatologic Diseases 2022. [DOI: 10.1007/978-3-030-92616-8_15] [Reference Citation Analysis]
192 Liu D, Gao S, Zhai Y, Yang X, Zhai G. Research progress of tumor targeted drug delivery based on PD-1/PD-L1. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
193 Mandal A, Varghese MV, James J. Present Status of the Therapeutic Approaches to Treat Uveal Melanoma. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-1247-3_199-1] [Reference Citation Analysis]
194 Indini A, Pappo AS, Eigentler TK, Collini P, Ferrari A. Cutaneous Melanoma. Pediatric Oncology 2022. [DOI: 10.1007/978-3-030-92071-5_40] [Reference Citation Analysis]
195 Zhang HC, Wang LS, Miller E. Hepatology (Liver and Bile Duct). Managing Immunotherapy Related Organ Toxicities 2022. [DOI: 10.1007/978-3-031-00241-0_7] [Reference Citation Analysis]
196 Alam IS, Shaffer TM, Gambhir SS. Nuclear Imaging of Endogenous Markers of Lymphocyte Response. Nuclear Medicine and Immunology 2022. [DOI: 10.1007/978-3-030-81261-4_2] [Reference Citation Analysis]
197 Keshavarz-fathi M, Keshavarz-fathi M, Rezaei N. Cancer Immunology. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00083-5] [Reference Citation Analysis]
198 Mandal A, Varghese MV, James J. Present Status of the Therapeutic Approaches to Treat Uveal Melanoma. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-5422-0_199] [Reference Citation Analysis]
199 Kumar A, Weller KP, Vilgelm AE. Personalized cancer immunotherapy. Engineering Technologies and Clinical Translation 2022. [DOI: 10.1016/b978-0-323-90949-5.00012-7] [Reference Citation Analysis]
200 Berendika J, Jungić S, Tubić B, Rakita I, Vještica M, Đokanović D, Gojković Z, Mirčeta N, Petković S, Marković-peković V. First experiences with the use of targeted and immunotherapy in the treatment of cutaneous melanoma: A single centre experience. Scripta Medica 2022;53:29-35. [DOI: 10.5937/scriptamed53-35184] [Reference Citation Analysis]
201 Ito N, Tani R, Obayashi F, Okamoto K, Toratani S, Okamoto T. A case of lichenoid oral mucositis associated with nivolumab therapy. Oral Science International 2022;19:68-71. [DOI: 10.1002/osi2.1113] [Reference Citation Analysis]
202 Khalil R, Kassab A, Costa G, Haddad F, Richa S, Kattan J. Increased psychomotor retardation and tension as short-term neuropsychiatric adverse events of immune checkpoint inhibitors: A prospective cohort study. J Can Res Ther 2022;18:140. [DOI: 10.4103/jcrt.jcrt_1088_20] [Reference Citation Analysis]
203 Chow M, Sangalang EA, Chow C, Daud AI. Immunotherapy in Melanoma and Merkel Cell Cancer. Cancer Metastasis Through the Lymphovascular System 2022. [DOI: 10.1007/978-3-030-93084-4_67] [Reference Citation Analysis]
204 Dhanyamraju PK, Patel TN. Melanoma therapeutics: a literature review. J Biomed Res 2022;36:77. [DOI: 10.7555/jbr.36.20210163] [Reference Citation Analysis]
205 Baldessari C, Pugliese G, Venturelli M, Greco S, Ferrara L, Longo G, Dominici M, Depenni R. Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab. J Oncol Pharm Pract 2021;:10781552211067424. [PMID: 34964671 DOI: 10.1177/10781552211067424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Voellger B, Zhang Z, Benzel J, Wang J, Lei T, Nimsky C, Bartsch JW. Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review. J Clin Med 2021;11:124. [PMID: 35011868 DOI: 10.3390/jcm11010124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
207 Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2021;12:794099. [PMID: 34950153 DOI: 10.3389/fimmu.2021.794099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
208 Ferrucci PF, Cocorocchio E. Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers 2021;14:81. [DOI: 10.3390/cancers14010081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov 2021. [PMID: 34937915 DOI: 10.1038/s41573-021-00345-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
210 Sun Y, Zhao J, Sun X, Ma G. Identification of TNFAIP8 as an Immune-Related Biomarker Associated With Tumorigenesis and Prognosis in Cutaneous Melanoma Patients. Front Genet 2021;12:783672. [PMID: 34925463 DOI: 10.3389/fgene.2021.783672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
211 Chen Y, Zheng X, Wu C. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Front Immunol 2021;12:792691. [PMID: 34925375 DOI: 10.3389/fimmu.2021.792691] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
212 Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther 2021;6:424. [PMID: 34924562 DOI: 10.1038/s41392-021-00827-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
213 Schweighofer-Zwink G, Manafi-Farid R, Kölblinger P, Hehenwarter L, Harsini S, Pirich C, Beheshti M. Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy. Eur J Radiol 2022;146:110107. [PMID: 34922117 DOI: 10.1016/j.ejrad.2021.110107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
214 Ma R, Liu Y, Che X, Li C, Wen T, Hou K, Qu X. Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3. Cancer Lett 2021;527:127-39. [PMID: 34923044 DOI: 10.1016/j.canlet.2021.12.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Alemohammad H, Najafzadeh B, Asadzadeh Z, Baghbanzadeh A, Ghorbaninezhad F, Najafzadeh A, Safarpour H, Bernardini R, Brunetti O, Sonnessa M, Fasano R, Silvestris N, Baradaran B. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomed Pharmacother 2021;146:112516. [PMID: 34906767 DOI: 10.1016/j.biopha.2021.112516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
216 Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci 2021;22:13311. [PMID: 34948104 DOI: 10.3390/ijms222413311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
217 Qian J, Ding W, Jiang Y, Xu L. Meta-Analysis of irAEs between Dose of CTLA-4 and PD-1 Inhibitors. 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 2021. [DOI: 10.1109/bibm52615.2021.9669586] [Reference Citation Analysis]
218 Bossi P, Lorini L. Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations. Dermatol Pract Concept 2021;11:e2021170S. [PMID: 34877078 DOI: 10.5826/dpc.11S2a170S] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
219 Schulz D, Wetzel M, Eichberger J, Piendl G, Brockhoff G, Wege AK, Reichert TE, Ettl T, Bauer RJ. Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2021;22:13087. [PMID: 34884892 DOI: 10.3390/ijms222313087] [Reference Citation Analysis]
220 Machiraju D, Schäfer S, Hassel JC. Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma. Life (Basel) 2021;11:1318. [PMID: 34947849 DOI: 10.3390/life11121318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Amabile S, Roccuzzo G, Pala V, Tonella L, Rubatto M, Merli M, Fava P, Ribero S, Fierro MT, Queirolo P, Quaglino P. Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. J Clin Med 2021;10:5475. [PMID: 34884176 DOI: 10.3390/jcm10235475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Khaddour K, Maahs L, Avila-Rodriguez AM, Maamar Y, Samaan S, Ansstas G. Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers (Basel) 2021;13:5847. [PMID: 34831002 DOI: 10.3390/cancers13225847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
223 Vale L, Kunonga P, Coughlan D, Kontogiannis V, Astin M, Beyer F, Richmond C, Wilson D, Bajwa D, Javanbakht M, Bryant A, Akor W, Craig D, Lovat P, Labus M, Nasr B, Cunliffe T, Hinde H, Shawgi M, Saleh D, Royle P, Steward P, Lucas R, Ellis R. Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model. Health Technol Assess 2021;25:1-178. [PMID: 34792018 DOI: 10.3310/hta25640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Yang YL, Li ZQ, Wang QL, Gu JJ, Fang XJ, Huang GH. Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review. Clin Ther 2021:S0149-2918(21)00391-X. [PMID: 34794831 DOI: 10.1016/j.clinthera.2021.09.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Zhang XT, Chen H, Shao W, Lin ZJ, Melhem M, Lu S. A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open 2021;7. [DOI: 10.1186/s41120-021-00039-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
226 Sun D, Guan X, Moran AE, Wu LY, Qian DZ, Schedin P, Dai MS, Danilov AV, Alumkal JJ, Adey AC, Spellman PT, Xia Z. Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat Biotechnol 2021. [PMID: 34764492 DOI: 10.1038/s41587-021-01091-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
227 Rossi E, Schinzari G, Maiorano BA, Esposito I, Acampora A, Romagnoli J, Stefani AD, Regno LD, Lancellotta V, Fionda B, Tagliaferri L, Peris K, Tortora G. Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. Immunotherapy 2021. [PMID: 34751039 DOI: 10.2217/imt-2021-0195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
228 Sun YM, Li W, Chen ZY, Wang Y. Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:651553. [PMID: 34745932 DOI: 10.3389/fonc.2021.651553] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
229 Fink M, Vittrup AS, Bastholt L, Svane IM, Donia M, Luczak AA, Ruhlmann CH, Guldbrandt LM, Koehler UH, Winther ML, Ellebaek E, Haslund CA, Schmidt H. Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers (Basel) 2021;13:5550. [PMID: 34771712 DOI: 10.3390/cancers13215550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
230 Anderson EM, Thomassian S, Gong J, Hendifar A, Osipov A. Advances in Pancreatic Ductal Adenocarcinoma Treatment. Cancers (Basel) 2021;13:5510. [PMID: 34771675 DOI: 10.3390/cancers13215510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
231 Yang W, Lei C, Song S, Jing W, Jin C, Gong S, Tian H, Guo T. Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. Cancer Cell Int 2021;21:589. [PMID: 34727927 DOI: 10.1186/s12935-021-02299-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
232 Brix N, Dunn L, Seiwert T, Belka C, Lauber K. Immuntherapie bei Kopf-Hals-Plattenepithelkarzinomen. best practice onkologie 2021;16:520-527. [DOI: 10.1007/s11654-021-00347-3] [Reference Citation Analysis]
233 Maeda E, Akita M, Nishimura T, Abe K, Kozuki A, Yokoyama K, Tanaka T, Kishi S, Ichikawa C, Imai Y, Kaneda K. Successful Conversion Surgery Following Bullous Pemphigoid after Nivolumab for Advanced Gastric Cancer. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2021;54:802-812. [DOI: 10.5833/jjgs.2020.0175] [Reference Citation Analysis]
234 Jazirehi AR. Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy. Int J Mol Sci 2021;22:11726. [PMID: 34769156 DOI: 10.3390/ijms222111726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
235 Katano I, Hanazawa A, Otsuka I, Yamaguchi T, Mochizuki M, Kawai K, Ito R, Goto M, Kagawa T, Takahashi T. Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody. Sci Rep 2021;11:21087. [PMID: 34702924 DOI: 10.1038/s41598-021-00641-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
236 Kunatoga A, Mohammadnezhad M. Health services related factors affecting the pap smear services in Fiji: a qualitative study. BMC Health Serv Res 2021;21:1154. [PMID: 34696802 DOI: 10.1186/s12913-021-07176-8] [Reference Citation Analysis]
237 Hao Z, Li R, Wang Y, Li S, Hong Z, Han Z. Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy. Biomark Res 2021;9:77. [PMID: 34689842 DOI: 10.1186/s40364-021-00333-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
238 Marable J, Ruiz D, Jaiswal AK, Bhattacharya R, Pantazes R, Agarwal P, Suryawanshi AS, Bedi D, Mishra A, Smith BF, Sandey M. Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients. Sci Rep 2021;11:20763. [PMID: 34675296 DOI: 10.1038/s41598-021-00325-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
239 Zhou W, Zhou Y, Yi C, Shu X, Wei G, Chen X, Shen X, Qiu M. Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody. Front Immunol 2021;12:749204. [PMID: 34659249 DOI: 10.3389/fimmu.2021.749204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
240 Heidecker B. Potential Novel Therapeutic Target to Improve Graft Survival: New Insights Into the Role of Checkpoint Molecules in Heart Transplant Rejection. Circ Heart Fail 2021;14:e008859. [PMID: 34634915 DOI: 10.1161/CIRCHEARTFAILURE.121.008859] [Reference Citation Analysis]
241 Balakrishnan PB, Ledezma DK, Cano-mejia J, Andricovich J, Palmer E, Patel VA, Latham PS, Yvon ES, Villagra A, Fernandes R, Sweeney EE. CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. Nano Res 2022;15:2300-14. [DOI: 10.1007/s12274-021-3813-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Tian T, Li Z. Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade. Front Oncol 2021;11:731175. [PMID: 34631560 DOI: 10.3389/fonc.2021.731175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
243 Kim RY, Mitra N, Bagley SJ, Marmarelis ME, Haas AR, Rendle KA, Vachani A. Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma. JTO Clin Res Rep 2021;2:100188. [PMID: 34590032 DOI: 10.1016/j.jtocrr.2021.100188] [Reference Citation Analysis]
244 Xu Q, Chen S, Hu Y, Huang W. Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma. Front Genet 2021;12:739975. [PMID: 34589117 DOI: 10.3389/fgene.2021.739975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
245 L'Orphelin JM, Varey E, Khammari A, Dreno B, Dompmartin A. Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases. Cancers (Basel) 2021;13:4928. [PMID: 34638410 DOI: 10.3390/cancers13194928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
246 Phakham T, Bulaon CJI, Khorattanakulchai N, Shanmugaraj B, Buranapraditkun S, Boonkrai C, Sooksai S, Hirankarn N, Abe Y, Strasser R, Rattanapisit K, Phoolcharoen W. Functional Characterization of Pembrolizumab Produced in Nicotiana benthamiana Using a Rapid Transient Expression System. Front Plant Sci 2021;12:736299. [PMID: 34567049 DOI: 10.3389/fpls.2021.736299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
247 Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, Zamyatnin AA Jr, Ganjalikhani-Hakemi M. mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines (Basel) 2021;9:1060. [PMID: 34696168 DOI: 10.3390/vaccines9101060] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
248 Kong F, Wang Z, Liao D, Zuo J, Xie H, Li X, Jia Y. Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance. Front Oncol 2021;11:739191. [PMID: 34532293 DOI: 10.3389/fonc.2021.739191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
249 Liang J, Zhang H, Huang Y, Fan L, Li F, Li M, Yan Y, Zhang J, Li Z, Yang X. A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy. Cancer Manag Res 2021;13:6977-87. [PMID: 34522140 DOI: 10.2147/CMAR.S330637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
250 Ziogas DC, Gkoufa A, Cholongitas E, Diamantopoulos P, Anastasopoulou A, Ascierto PA, Gogas H. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer 2020;8:e001322. [PMID: 33144335 DOI: 10.1136/jitc-2020-001322] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
251 Castillo AMM, Vu TT, Liva SG, Chen M, Xie Z, Thomas J, Remaily B, Guo Y, Subrayan UL, Costa T, Helms TH, Irby DJ, Kim K, Owen DH, Kulp SK, Mace TA, Phelps MA, Coss CC. Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. JCSM Rapid Commun 2021;4:232-44. [PMID: 34514376 DOI: 10.1002/rco2.32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
252 Wang L, Han H, Wang Z, Shi L, Yang M, Qin Y. Targeting the Microenvironment in Esophageal Cancer. Front Cell Dev Biol 2021;9:684966. [PMID: 34513829 DOI: 10.3389/fcell.2021.684966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
253 Li X, Qu LX, Ren YM, Hu C. Case Report: A Case Report and Literature Review on Severe Bullous Skin Reaction Induced by anti-PD-1 Immunotherapy in a Cervical Cancer Patient. Front Pharmacol 2021;12:707967. [PMID: 34504425 DOI: 10.3389/fphar.2021.707967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
254 Wohlmuth C, Wohlmuth-Wieser I. Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. Am J Clin Dermatol 2021;22:639-51. [PMID: 34125416 DOI: 10.1007/s40257-021-00614-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
255 Lecuelle J, Boidot R, Mananet H, Derangère V, Albuisson J, Goussot V, Arnould L, Tharin Z, Ray Coquard I, Ghiringhelli F, Truntzer C, Fumet JD. TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer. Cancers (Basel) 2021;13:4394. [PMID: 34503204 DOI: 10.3390/cancers13174394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Makunts T, Saunders IM, Cohen IV, Li M, Moumedjian T, Issa MA, Burkhart K, Lee P, Patel SP, Abagyan R. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep 2021;11:17324. [PMID: 34462476 DOI: 10.1038/s41598-021-96467-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
257 Ge Y, Zhang H, Weygant N, Yao J. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Front Pharmacol 2021;12:640099. [PMID: 34447305 DOI: 10.3389/fphar.2021.640099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
258 Quaglino P, Fava P, Tonella L, Rubatto M, Ribero S, Fierro MT. Treatment of Advanced Metastatic Melanoma. Dermatol Pract Concept 2021;11:e2021164S. [PMID: 34447613 DOI: 10.5826/dpc.11S1a164S] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
259 Laria A, Lurati A, Castelnovo L, Tamburello A, Faggioli PM, Mazzone A. Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series. Beyond Rheumatol 2021;3. [DOI: 10.4081/br.2021.65] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
260 Makaremi S, Asadzadeh Z, Hemmat N, Baghbanzadeh A, Sgambato A, Ghorbaninezhad F, Safarpour H, Argentiero A, Brunetti O, Bernardini R, Silvestris N, Baradaran B. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines 2021;9:1075. [PMID: 34572263 DOI: 10.3390/biomedicines9091075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
261 Xu Q, Xu H, Chen S, Huang W. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:710207. [PMID: 34409040 DOI: 10.3389/fcell.2021.710207] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
262 Talwar J, Laub D, Pagadala M, Castro A, Lewis M, Luebeck GE, Gorman B, Pan C, Dong FN, Markianos K, Hauger R, Pyarajan S, Tsao PS, Morris GP, Salem RM, Thompson WK, Curtius K, Zanetti M, Carter H. Autoimmune Alleles at the Major Histocompatibility Locus Modify Melanoma Susceptibility.. [DOI: 10.1101/2021.08.12.456166] [Reference Citation Analysis]
263 Naik PP. Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. Dermatol Ther (Heidelb) 2021. [PMID: 34339016 DOI: 10.1007/s13555-021-00583-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
264 Chen K, Sun B. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis]. Zhongguo Fei Ai Za Zhi 2020;23:927-40. [PMID: 33203196 DOI: 10.3779/j.issn.1009-3419.2020.103.14] [Reference Citation Analysis]
265 Liu Z, Li S, Huang S, Wang T, Liu Z. N6-Methyladenosine Regulators and Related LncRNAs Are Potential to be Prognostic Markers for Uveal Melanoma and Indicators of Tumor Microenvironment Remodeling. Front Oncol 2021;11:704543. [PMID: 34395276 DOI: 10.3389/fonc.2021.704543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
266 Khairil Anwar NA, Mohd Nazri MN, Murtadha AH, Mohd Adzemi ER, Balakrishnan V, Mustaffa KMF, Tengku Din TADA, Yahya MM, Haron J, Mokshtar NF. Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. Acta Biochim Biophys Sin (Shanghai) 2021;53:961-78. [PMID: 34180502 DOI: 10.1093/abbs/gmab077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
267 Huang S, Deng W, Wang P, Yan Y, Xie C, Cao X, Chen M, Zhang C, Shi D, Dong Y, Cheng P, Xu H, Zhu W, Hu Z, Tang B, Zhu J. Fermitin family member 2 promotes melanoma progression by enhancing the binding of p-α-Pix to Rac1 to activate the MAPK pathway. Oncogene 2021. [PMID: 34321603 DOI: 10.1038/s41388-021-01954-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
268 Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov 2021. [PMID: 34316029 DOI: 10.1038/s41573-021-00259-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
269 Subasri M, Lemonde M, Mundluru J, Chang J, Koneru R. Assessing the Educational and Supportive Care Needs of Canadian Metastatic Melanoma Patients and Survivors Attending an Outpatient Clinic. J Patient Exp 2021;8:23743735211033126. [PMID: 34368426 DOI: 10.1177/23743735211033126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
270 Patel A, Abid H, Kumar A. The Endocrinological Side Effects of Immunotherapies. Advances in Precision Medicine Oncology 2021. [DOI: 10.5772/intechopen.96491] [Reference Citation Analysis]
271 Favara DM, Spain L, Au L, Clark J, Daniels E, Diem S, Chauhan D, Turajlic S, Powell N, Larkin JM, Yousaf N. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open. 2020;5. [PMID: 32641348 DOI: 10.1136/esmoopen-2019-000585] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
272 Kiselevsky MV, Samoylenko IV, Zharkova OV, Ziganshina NV, Petkevich AA, Sitdikova SM, Suleymanova AM, Sagoyan GB, Efimova MM, Kirgizov KI, Varfolomeeva SR. Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors. Ross ž det gematol onkol 2021;8:73-83. [DOI: 10.21682/2311-1267-2021-8-2-73-83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
273 Tian Y, Li R, Liu Y, Li M, Song Y, Zheng Y, Gao A, Wen Q, Su G, Sun Y. The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:667650. [PMID: 34322382 DOI: 10.3389/fonc.2021.667650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
274 Wang J, Li F, Xu Y, Zheng X, Zhang C, Hu C, Xu Y, Mi W, Li X, Zhang Y. Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma. J Transl Med 2021;19:296. [PMID: 34238310 DOI: 10.1186/s12967-021-02962-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
275 Zou W, Lu J, Hao Y. Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. J Inflamm Res 2021;14:3077-88. [PMID: 34267536 DOI: 10.2147/JIR.S311616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
276 Zhao Y, Liu L, Weng L. Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Front Pharmacol 2021;12:714483. [PMID: 34305619 DOI: 10.3389/fphar.2021.714483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
277 Xu Q, Xu H, Deng R, Wang Z, Li N, Qi Z, Zhao J, Huang W. Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma. Cancer Cell Int 2021;21:342. [PMID: 34217320 DOI: 10.1186/s12935-021-02049-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
278 Coen O, Corrie P, Marshall H, Plummer R, Ottensmeier C, Hook J, Bell S, Sagoo GS, Meads D, Bestall J, Velikova G, Gallagher FA, Smith A, Howard H, Mason E, Katona E, Silva S, Collinson M, Rodwell S, Danson S. The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer 2021;21:761. [PMID: 34210290 DOI: 10.1186/s12885-021-08509-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
279 Russell BL, Sooklal SA, Malindisa ST, Daka LJ, Ntwasa M. The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Front Oncol 2021;11:641428. [PMID: 34268109 DOI: 10.3389/fonc.2021.641428] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
280 Yu L, Liu X, Wang X, Yan F, Wang P, Jiang Y, Du J, Yang Z. TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma. Oncoimmunology 2021;10:1942673. [PMID: 34249476 DOI: 10.1080/2162402X.2021.1942673] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
281 Dong Y, Li Q, Miao Q, Li D. Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review. Medicine (Baltimore) 2021;100:e26450. [PMID: 34160440 DOI: 10.1097/MD.0000000000026450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
282 Bobircă A, Bobircă F, Ancuta I, Florescu A, Pădureanu V, Florescu DN, Pădureanu R, Florescu A, Mușetescu AE. Rheumatic Immune-Related Adverse Events-A Consequence of Immune Checkpoint Inhibitor Therapy. Biology (Basel) 2021;10:561. [PMID: 34203101 DOI: 10.3390/biology10060561] [Reference Citation Analysis]
283 Liu B, Fu T, He P, Du C, Xu K. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer. Biosci Rep 2021;41:BSR20204301. [PMID: 34143198 DOI: 10.1042/BSR20204301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
284 Ma SC, Zhu HB, Wang J, Zhang YP, Guo XJ, Long LL, Guo ZQ, Wu DH, Dong ZY, Bai X. De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma. Front Oncol 2021;11:666145. [PMID: 34221982 DOI: 10.3389/fonc.2021.666145] [Reference Citation Analysis]
285 Sliker BH, Campbell PM. Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. Vaccines (Basel) 2021;9:634. [PMID: 34200702 DOI: 10.3390/vaccines9060634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
286 Naing A, Gainor JF, Gelderblom H, Forde PM, Butler MO, Lin CC, Sharma S, Ochoa de Olza M, Varga A, Taylor M, Schellens JHM, Wu H, Sun H, Silva AP, Faris J, Mataraza J, Cameron S, Bauer TM. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer 2020;8:e000530. [PMID: 32179633 DOI: 10.1136/jitc-2020-000530] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 19.0] [Reference Citation Analysis]
287 Lussier DM, Alspach E, Ward JP, Miceli AP, Runci D, White JM, Mpoy C, Arthur CD, Kohlmiller HN, Jacks T, Artyomov MN, Rogers BE, Schreiber RD. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A 2021;118:e2102611118. [PMID: 34099555 DOI: 10.1073/pnas.2102611118] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
288 Stein MK, Oluoha O, Patel K, VanderWalde A. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. J Pers Med 2021;11:518. [PMID: 34198738 DOI: 10.3390/jpm11060518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
289 Nakata J, Isohashi K, Oka Y, Nakajima H, Morimoto S, Fujiki F, Oji Y, Tsuboi A, Kumanogoh A, Hashimoto N, Hatazawa J, Sugiyama H. Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics (Basel) 2021;11. [PMID: 34198874 DOI: 10.3390/diagnostics11061041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
290 Feng L, Yang L, Li L, Xiao J, Bie N, Xu C, Zhou J, Liu H, Gan L, Wu Y. Programmed albumin nanoparticles regulate immunosuppressive pivot to potentiate checkpoint blockade cancer immunotherapy. Nano Res 2022;15:593-602. [DOI: 10.1007/s12274-021-3525-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
291 Dastmalchi F, Deleyrolle LP, Karachi A, Mitchell DA, Rahman M. Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy. Front Oncol 2021;11:691246. [PMID: 34150663 DOI: 10.3389/fonc.2021.691246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
292 Rachev B, Wilking N, Kobelt G, Spandonaro F, Rajer M, Roediger A, Normand R, Zielinski C. Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets. Journal of Cancer Policy 2021;28:100279. [DOI: 10.1016/j.jcpo.2021.100279] [Reference Citation Analysis]
293 Kuo YH, Yen YH, Chen YY, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Front Oncol 2021;11:683341. [PMID: 34136408 DOI: 10.3389/fonc.2021.683341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
294 Hu J, Tian R, Ma Y, Zhen H, Ma X, Su Q, Cao B. Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:645245. [PMID: 34123795 DOI: 10.3389/fonc.2021.645245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
295 Bezerra Toscano de Mendonça U, Guimarães Soffientini J, Ficher Barbosa V, Cozer K. Mucosal Melanoma of the Head and Neck: From Diagnosis to Treatment. Melanoma 2021. [DOI: 10.5772/intechopen.93804] [Reference Citation Analysis]
296 Tian Y, Huang A, Yang Y, Dang Q, Wen Q, Wang L, Sun Y. Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:662392. [PMID: 34109117 DOI: 10.3389/fonc.2021.662392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Sawada Y, Nakatsuji T, Dokoshi T, Kulkarni NN, Liggins MC, Sen G, Gallo RL. Cutaneous innate immune tolerance is mediated by epigenetic control of MAP2K3 by HDAC8/9. Sci Immunol 2021;6:eabe1935. [PMID: 34021025 DOI: 10.1126/sciimmunol.abe1935] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
298 Benjamin A B, Gboyega E A, Samuel E A. Mechanistic basis for Cancer Immune Evasion and role of immune checkpoint blockades in Immuno-Oncology. Glob J Cancer Ther 2021. [DOI: 10.17352/2581-5407.000040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
299 Azuma T, Takeuchi T, Matayoshi Y, Namiki S, Obara T, Imamura K, Takamori M. Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. Sci Rep 2021;11:10264. [PMID: 33986326 DOI: 10.1038/s41598-021-88744-0] [Reference Citation Analysis]
300 Munari E, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, Eccher A, Ciompi F, Brunelli M, Martignoni G, Bogina G, Moretta L. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. Int J Mol Sci 2021;22:5123. [PMID: 34066087 DOI: 10.3390/ijms22105123] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 13.5] [Reference Citation Analysis]
301 Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol 2021;39:2656-66. [PMID: 33979178 DOI: 10.1200/JCO.21.00612] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 24.0] [Reference Citation Analysis]
302 Bai R, Li L, Chen X, Chen N, Song W, Zhang Y, Lv Z, Han F, Zhao Y, Li W, Cui J. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors. J Oncol 2021;2021:9935076. [PMID: 34335763 DOI: 10.1155/2021/9935076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
303 Butner JD, Martin GV, Wang Z, Corradetti B, Ferrari M, Esnaola N, Chung C, Hong DS, Welsh J, Hasegawa N, Mittendorf EA, Curley SA, Chen S, Pan P, Libutti SK, Ganesan S, Sidman RL, Pasqualini R, Arap W, Koay EJ, Cristini V. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling.. [DOI: 10.1101/2021.05.10.21256419] [Reference Citation Analysis]
304 Saito-Sasaki N, Sawada Y, Okada E, Nakamura M. Cell Adhesion Molecule 1 (CADM1) Is an Independent Prognostic Factor in Patients with Cutaneous Squamous Cell Carcinoma. Diagnostics (Basel) 2021;11:830. [PMID: 34064472 DOI: 10.3390/diagnostics11050830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
305 Zhu G, Su H, Johnson CH, Khan SA, Kluger H, Lu L. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. Eur J Cancer 2021;151:25-34. [PMID: 33962358 DOI: 10.1016/j.ejca.2021.03.053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
306 Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, Schrag D. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open 2021;4:e2111113. [PMID: 34019086 DOI: 10.1001/jamanetworkopen.2021.11113] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
307 Liu J, Cao F, Li X, Zhang L, Liu Z, Li X, Lin J, Han C. ITIH5, a p53-responsive gene, inhibits the growth and metastasis of melanoma cells by downregulating the transcriptional activity of KLF4. Cell Death Dis 2021;12:438. [PMID: 33935281 DOI: 10.1038/s41419-021-03707-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
308 Ziogas DC, Konstantinou F, Bouros S, Theochari M, Gogas H. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. Am J Clin Dermatol 2021;22:301-14. [PMID: 33765322 DOI: 10.1007/s40257-021-00593-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
309 Mangin MA, Boespflug A, Maucort Boulch D, Vacheron CH, Carpentier I, Thomas L, Dalle S. Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma. Cancer Med 2021;10:3155-64. [PMID: 33932099 DOI: 10.1002/cam4.3760] [Reference Citation Analysis]
310 Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, Hu X, Wang ZW. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther 2021;29:1958-69. [PMID: 33932597 DOI: 10.1016/j.ymthe.2021.04.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
311 Jagieła J, Bartnicki P, Rysz J. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:4618. [PMID: 33924827 DOI: 10.3390/ijms22094618] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
312 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
313 Grabbe P, Gschwendtner KM, Maatouk I, Strobel SB, Salzmann M, Bossert J, Eich W, Wild B, Meier F, Hassel JC, Bieber C. Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. Trials 2021;22:294. [PMID: 33879219 DOI: 10.1186/s13063-021-05234-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
314 Spagnolo F, Boutros A, Cecchi F, Croce E, Tanda ET, Queirolo P. Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. BMC Cancer 2021;21:425. [PMID: 33865350 DOI: 10.1186/s12885-021-08165-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
315 Ma W, Zhang K, Bao Z, Jiang T, Zhang Y. SAMD9 Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma. Front Immunol 2021;12:659659. [PMID: 33936093 DOI: 10.3389/fimmu.2021.659659] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
316 Jiang J, Jin Z, Zhang Y, Peng L, Zhang Y, Zhu Z, Wang Y, Tong, Yang Y, Wang J, Yang Y, Xiao K. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. Front Immunol 2021;12:646874. [PMID: 33927719 DOI: 10.3389/fimmu.2021.646874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
317 Zhou H, Chen L, Qin M, Lei Y, Li T, Li H, Cheng X. An miRNA signature associated with tumor mutation burden in endometrial cancer. Biosci Rep 2020;40:BSR20203398. [PMID: 33141168 DOI: 10.1042/BSR20203398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
318 Garutti M, Bonin S, Buriolla S, Bertoli E, Pizzichetta MA, Zalaudek I, Puglisi F. Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. Cancers (Basel) 2021;13:1819. [PMID: 33920288 DOI: 10.3390/cancers13081819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
319 He HX, Gao Y, Fu JC, Zhou QH, Wang XX, Bai B, Li PF, Huang C, Rong QX, Ping LQ, He YX, Mao JY, Chen X, Huang HQ. VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma. Oncoimmunology 2021;10:1907059. [PMID: 33889438 DOI: 10.1080/2162402X.2021.1907059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
320 Taira K, Kimura A, Nakata A, Nadatani Y, Fukunaga S, Otani K, Hosomi S, Tanaka F, Kamata N, Nagami Y, Watanabe T, Fujiwara Y. A case of nivolumab-induced cervical lymphadenopathy in a patient with gastric cancer. J Gastrointest Oncol 2021;12:880-4. [PMID: 34012675 DOI: 10.21037/jgo-20-315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
321 Jeong SD, Jung BK, Ahn HM, Lee D, Ha J, Noh I, Yun CO, Kim YC. Immunogenic Cell Death Inducing Fluorinated Mitochondria-Disrupting Helical Polypeptide Synergizes with PD-L1 Immune Checkpoint Blockade. Adv Sci (Weinh) 2021;8:2001308. [PMID: 33854870 DOI: 10.1002/advs.202001308] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
322 Bong CY, Smithers BM, Chua TC. Pulmonary metastasectomy in the era of targeted therapy and immunotherapy. J Thorac Dis 2021;13:2618-27. [PMID: 34012610 DOI: 10.21037/jtd.2020.03.120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
323 Li Q, Dong Y, Pan Y, Tang H, Li D. Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma. Front Immunol 2021;12:634559. [PMID: 33868256 DOI: 10.3389/fimmu.2021.634559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
324 Cunha Pereira T, Rodrigues-Santos P, Almeida JS, Rêgo Salgueiro F, Monteiro AR, Macedo F, Soares RF, Domingues I, Jacinto P, Sousa G. Immunotherapy and predictive immunologic profile: the tip of the iceberg. Med Oncol 2021;38:51. [PMID: 33788049 DOI: 10.1007/s12032-021-01497-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
325 Verver D, Grünhagen DJ, van Akkooi ACJ, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Tije AJT, Vreugdenhil G, Verhoef C, van der Veldt AAM. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. Cancer Immunol Immunother 2021;70:3123-35. [PMID: 33774697 DOI: 10.1007/s00262-021-02871-1] [Reference Citation Analysis]
326 Wang X, Lu J, Guo G, Yu J. Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects. Cell Death Dis 2021;12:299. [PMID: 33741903 DOI: 10.1038/s41419-021-03568-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
327 Song J, Jin C, Chen E, Dong X, Zhu L. L Antigen Family Member 3 Serves as a Prognostic Biomarker for the Clinical Outcome and Immune Infiltration in Skin Cutaneous Melanoma. Biomed Res Int 2021;2021:6648182. [PMID: 33829062 DOI: 10.1155/2021/6648182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
328 Kadokawa Y, Takagi M, Yoshida T, Tatsumi A, Fujita K, Inoue T, Ohe S, Nakai Y, Yamamoto S, Otsuka T, Ishihara R, Isei T, Kumagai T, Nishimura K, Imamura F. Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study. Mol Clin Oncol 2021;14:65. [PMID: 33680456 DOI: 10.3892/mco.2021.2227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
329 Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med 2021;10:2293-9. [PMID: 33686688 DOI: 10.1002/cam4.3781] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
330 Keilson JM, Knochelmann HM, Paulos CM, Kudchadkar RR, Lowe MC. The evolving landscape of immunotherapy in solid tumors. J Surg Oncol 2021;123:798-806. [PMID: 33595890 DOI: 10.1002/jso.26416] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
331 Lu S, Sun Z, Hu W, Yin S, Zhao C, Hu H. PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B. Cancer Sci 2021;112:1878-87. [PMID: 33583114 DOI: 10.1111/cas.14844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
332 Gillis A, Ben Yaacov A, Agur Z. A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker. Front Immunol 2021;12:616881. [PMID: 33732241 DOI: 10.3389/fimmu.2021.616881] [Reference Citation Analysis]
333 Han J, Zhao Y, Shirai K, Molodtsov A, Kolling FW, Fisher JL, Zhang P, Yan S, Searles TG, Bader JM, Gui J, Cheng C, Ernstoff MS, Turk MJ, Angeles CV. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat Cancer 2021;2:300-11. [PMID: 34179824 DOI: 10.1038/s43018-021-00180-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
334 López CR, García TC, Pérez JP, González MM, Pose VV. Melanoma cutáneo. Medicine - Programa de Formación Médica Continuada Acreditado 2021;13:1493-1505. [DOI: 10.1016/j.med.2021.03.001] [Reference Citation Analysis]
335 Boussios S, Sheriff M, Rassy E, Moschetta M, Samartzis EP, Hallit R, Sadauskaite A, Katsanos KH, Christodoulou DK, Pavlidis N. Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Ann Transl Med 2021;9:423. [PMID: 33842644 DOI: 10.21037/atm-20-7361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
336 Dong X, Song J, Chen B, Qi Y, Jiang W, Li H, Zheng D, Wang Y, Zhang X, Liu H. Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma. Front Oncol 2020;10:592811. [PMID: 33718105 DOI: 10.3389/fonc.2020.592811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
337 Naik PP. Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management. World J Oncol 2021;12:7-19. [PMID: 33738001 DOI: 10.14740/wjon1349] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
338 Tang H, Zhou J, Bai C. The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease. Front Oncol 2021;11:625872. [PMID: 33692958 DOI: 10.3389/fonc.2021.625872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
339 Reese SW, Cone E, Marchese M, Garcia B, Chou W, Ayub A, Kilbridge K, Weinhouse G, Trinh QD. Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. Lung 2021;199:199-211. [PMID: 33616727 DOI: 10.1007/s00408-021-00425-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
340 Jacob A, Wu J, Kolesar J, Durbin E, Mathew A, Arnold S, Chauhan A. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry. Cancer Med 2021;10:2054-62. [PMID: 33619913 DOI: 10.1002/cam4.3802] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
341 Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. JAMA Dermatol 2020;156:982-6. [PMID: 32667663 DOI: 10.1001/jamadermatol.2020.2149] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
342 Zhang H, Wang Y, Zheng Q, Tang K, Fang R, Wang Y, Sun Q. Research Interest and Public Interest in Melanoma: A Bibliometric and Google Trends Analysis. Front Oncol 2021;11:629687. [PMID: 33680968 DOI: 10.3389/fonc.2021.629687] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
343 Iafolla MAJ, Yang C, Chandran V, Pintilie M, Li Q, Bedard PL, Hansen A, Lheureux S, Spreafico A, Razak AA, Hakgor S, Giesler A, Pugh TJ, Siu LL. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. JNCI Cancer Spectr 2021;5:pkaa115. [PMID: 33554038 DOI: 10.1093/jncics/pkaa115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
344 Kelleher T, Cai J, Botwood NA, Labriola DF. Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors. J Immunother Cancer 2021;9:e001177. [PMID: 33558277 DOI: 10.1136/jitc-2020-001177] [Reference Citation Analysis]
345 Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, Agarwal N, Zakharia Y, Costello BA, McKay RR, Narayan V, Alva A, McGregor BA, Gao X, McDermott DF, Choueiri TK. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncol 2020;6:1606-10. [PMID: 32469396 DOI: 10.1001/jamaoncol.2020.2169] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 22.5] [Reference Citation Analysis]
346 Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, Kim HR, Park SH, Shin EC, Kim YY, Kim DJ, Chung HC, Chon HJ, Choi HJ, Lim HY. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol 2021;74:350-9. [PMID: 32810553 DOI: 10.1016/j.jhep.2020.08.010] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 37.0] [Reference Citation Analysis]
347 Lv H, Zhang J, Sun K, Nie C, Chen B, Wang J, Xu W, Wang S, Liu Y, Chen X. Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. Front Oncol 2020;10:580045. [PMID: 33598422 DOI: 10.3389/fonc.2020.580045] [Reference Citation Analysis]
348 Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment? Expert Opin Ther Targets 2021;25:141-51. [PMID: 33356674 DOI: 10.1080/14728222.2021.1869212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
349 Maity A, Mick R, Rengan R, Mitchell TC, Amaravadi RK, Schuchter LM, Pryma DA, Patsch DM, Maity AP, Minn AJ, Vonderheide RH, Lukens JN. A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. Oncoimmunology 2021;10:1863631. [PMID: 33643689 DOI: 10.1080/2162402X.2020.1863631] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
350 Duong SL, Barbiero FJ, Nowak RJ, Baehring JM. Neurotoxicities associated with immune checkpoint inhibitor therapy. J Neurooncol 2021;152:265-77. [PMID: 33454891 DOI: 10.1007/s11060-021-03695-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
351 Bae JH, Baek YH, Lee JE, Song I, Lee JH, Shin JY. Machine Learning for Detection of Safety Signals From Spontaneous Reporting System Data: Example of Nivolumab and Docetaxel. Front Pharmacol 2020;11:602365. [PMID: 33628176 DOI: 10.3389/fphar.2020.602365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
352 Armengol M, Santos JC, Fernández-Serrano M, Profitós-Pelejà N, Ribeiro ML, Roué G. Immune-Checkpoint Inhibitors in B-Cell Lymphoma. Cancers (Basel) 2021;13:E214. [PMID: 33430146 DOI: 10.3390/cancers13020214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
353 Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam PJ, Kockx M, Keyaerts M, Everaert H, Seremet T, Rogiers A, Neyns B. A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers (Basel) 2021;13:E168. [PMID: 33418936 DOI: 10.3390/cancers13020168] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
354 Li H, Xu J, Bai Y, Zhang S, Cheng M, Jin J. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Invest New Drugs 2021;39:860-70. [PMID: 33409896 DOI: 10.1007/s10637-020-01039-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
355 Jiang Q, Feng M, Li Y, Lang J, Wei H, Yu T. Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS. Front Pharmacol 2020;11:574511. [PMID: 33390946 DOI: 10.3389/fphar.2020.574511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
356 Ziogas IA, Evangeliou AP, Giannis D, Hayat MH, Mylonas KS, Tohme S, Geller DA, Elias N, Goyal L, Tsoulfas G. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist 2021;26:e1036-49. [PMID: 33314549 DOI: 10.1002/onco.13638] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
357 Myers JW, Peoples GE, Clifton GT. Overcoming Cancer Tolerance with Immune Checkpoint Blockade. Cancer Immunology 2021. [DOI: 10.1007/978-3-030-50287-4_6] [Reference Citation Analysis]
358 Botticelli A, Trojaniello C, Ascierto PA, Marchetti P. Immunotherapy. Practical Medical Oncology Textbook 2021. [DOI: 10.1007/978-3-030-56051-5_12] [Reference Citation Analysis]
359 Huang Q, Zheng Y, Gao Z, Yuan L, Sun Y, Chen H. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. J Cancer 2021;12:1133-43. [PMID: 33442411 DOI: 10.7150/jca.49325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
360 Patel AB, Pacha O. Skin Reactions to Immune Checkpoint Inhibitors. Advances in Experimental Medicine and Biology 2021. [DOI: 10.1007/978-3-030-79308-1_11] [Reference Citation Analysis]
361 Castello A, Lopci E. Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology 2021. [DOI: 10.1007/978-3-030-68858-5_8] [Reference Citation Analysis]
362 Goto H, Sugita K, Yamamoto O. Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease. Indian J Dermatol 2021;66:169-73. [PMID: 34188273 DOI: 10.4103/ijd.IJD_341_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
363 Lopes C, Morgado S, Plácido AI, Roque F, Morgado M. Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management. SN Compr Clin Med 2021;3:84-94. [DOI: 10.1007/s42399-020-00670-w] [Reference Citation Analysis]
364 Petrovsky A, Amosova V, Tumenko E, Linnik S, Obukhova O, Andramonova I, Tryakin A. Calculators for the assessment of need for drugs in oncology: justification of necessity and comparative characteristics. Med Tech Asses and Choice 2021. [DOI: 10.17116/medtech2021430119] [Reference Citation Analysis]
365 Chen P, Zheng Y, He H, Wang PY, Wang F, Liu SY. The role of endoscopic tumor length in resected esophageal squamous cell carcinoma: a retrospective study. J Thorac Dis 2021;13:353-61. [PMID: 33569215 DOI: 10.21037/jtd-21-108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
366 Tamariz Campillo AF, Corona Deschamps A, Mellado Orellana R, Díaz Greene EJ, Rodríguez Weber FL. Inhibidores de puntos de control inmunitario en estadios avanzados de melanoma. Acta Médica Grupo Ángeles 2021;19:108-115. [DOI: 10.35366/98579] [Reference Citation Analysis]
367 Queirolo P, Boutros A, Tanda ET. Cutaneous Melanoma and Other Skin Cancers. Practical Medical Oncology Textbook 2021. [DOI: 10.1007/978-3-030-56051-5_57] [Reference Citation Analysis]
368 Liu X, Liang X, Liang J, Li Y, Wang J. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review. Front Oncol 2020;10:530478. [PMID: 33365266 DOI: 10.3389/fonc.2020.530478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
369 Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Oncoimmunology 2020;10:1864909. [PMID: 33457084 DOI: 10.1080/2162402X.2020.1864909] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
370 Atwa SM, Handoussa H, Hosny KM, Odenthal M, El Tayebi HM. Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. World J Hepatol 2020; 12(12): 1211-1227 [PMID: 33442449 DOI: 10.4254/wjh.v12.i12.1211] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
371 Birzu C, French P, Caccese M, Cerretti G, Idbaih A, Zagonel V, Lombardi G. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. Cancers (Basel) 2020;13:E47. [PMID: 33375286 DOI: 10.3390/cancers13010047] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
372 Allegra A, Di Salvo E, Casciaro M, Musolino C, Pioggia G, Gangemi S. The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients. Biomedicines 2020;9:2. [PMID: 33375183 DOI: 10.3390/biomedicines9010002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
373 Sheth M, Ko J. Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma. Cancer Treat Res Commun 2021;26:100272. [PMID: 33338851 DOI: 10.1016/j.ctarc.2020.100272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
374 Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging 2021;48:1932-43. [PMID: 33336264 DOI: 10.1007/s00259-020-05137-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
375 Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Dholakia R, Ahmad H, Biniakewitz M, Condy M, Phelan H, Callahan M, Wong P, Singer S, Ariyan C, Bartlett EK, Crago A, Yoon S, Hwang S, Erinjeri JP, Qin LX, Tap WD, D'Angelo SP. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA Oncol 2020;6:402-8. [PMID: 31971541 DOI: 10.1001/jamaoncol.2019.6152] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 21.7] [Reference Citation Analysis]
376 Deng W, Wang Y, Liu X, Liu J, Wang L, Yang Z, Yang M, An Y, Tang C, Sanford NN, Kim BYS, Jiang W. Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. JAMA Netw Open 2020;3:e2028627. [PMID: 33295975 DOI: 10.1001/jamanetworkopen.2020.28627] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
377 Uhlig J, Biggemann L, Sheth A, Sharma R. Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. Digestive Disease Interventions 2020;04:373-381. [DOI: 10.1055/s-0040-1721404] [Reference Citation Analysis]
378 Nagai K. Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis. Front Med (Lausanne) 2020;7:584382. [PMID: 33251233 DOI: 10.3389/fmed.2020.584382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
379 Mariam A, Kamath S, Schveder K, Mcleod HL, Rotroff DM. Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors.. [DOI: 10.1101/2020.11.25.20238865] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
380 Modrakowska P, Balik K, Maj M, Bajek A. Novel therapies for advanced skin carcinomas. Postepy Dermatol Alergol 2020;37:660-70. [PMID: 33240003 DOI: 10.5114/ada.2020.100479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
381 Qi Y, Liu B, Sun Q, Xiong X, Chen Q. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. Front Immunol 2020;11:578877. [PMID: 33329549 DOI: 10.3389/fimmu.2020.578877] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
382 Kim PH, Suh CH, Kim HS, Kim KW, Kim DY, Lee EQ, Aizer AA, Guenette JP, Huang RY. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Korean J Radiol 2021;22:584-95. [PMID: 33289357 DOI: 10.3348/kjr.2020.0728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
383 Di Cintio F, Dal Bo M, Baboci L, De Mattia E, Polano M, Toffoli G. The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. Front Neurosci 2020;14:603647. [PMID: 33324155 DOI: 10.3389/fnins.2020.603647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
384 Specenier P. Cost-effectiveness of nivolumab in advanced melanoma: a drug review. Expert Rev Pharmacoecon Outcomes Res 2021;21:13-28. [PMID: 33225752 DOI: 10.1080/14737167.2021.1845144] [Reference Citation Analysis]
385 Biniakewitz MD, Kasler MK, Fessele KL. Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy. Asia Pac J Oncol Nurs 2021;8:18-24. [PMID: 33426185 DOI: 10.4103/apjon.apjon_48_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
386 In GK, Vaidya P, Filkins A, Hermel DJ, King KG, Ragab O, Tseng WW, Swanson M, Kokot N, Lang JE, Menendez L, DeClerck B, Kim G, Hu JC, Terando A, Jadvar H, Ricker C, Miller KA, Peng DH, Wysong A. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. J Cancer Res Clin Oncol 2021;147:1803-11. [PMID: 33210210 DOI: 10.1007/s00432-020-03458-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
387 Unterrainer M, Ruzicka M, Fabritius MP, Mittlmeier LM, Winkelmann M, Rübenthaler J, Brendel M, Subklewe M, von Bergwelt-Baildon M, Ricke J, Kunz WG, Cyran CC. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp 2020;4:63. [PMID: 33200246 DOI: 10.1186/s41747-020-00190-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
388 Huang YF, Xie WJ, Fan HY, Du J. Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. Front Oncol 2020;10:571135. [PMID: 33178599 DOI: 10.3389/fonc.2020.571135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
389 Chouljenko DV, Ding J, Lee IF, Murad YM, Bu X, Liu G, Delwar Z, Sun Y, Yu S, Samudio I, Zhao R, Jia WW. Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes. Biomedicines 2020;8:E484. [PMID: 33182232 DOI: 10.3390/biomedicines8110484] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
390 Hwang HS, Cherukula K, Bang YJ, Vijayan V, Moon MJ, Thiruppathi J, Puth S, Jeong YY, Park IK, Lee SE, Rhee JH. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression. Cells 2020;9:E2432. [PMID: 33171765 DOI: 10.3390/cells9112432] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
391 Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers (Basel) 2020;12:E3285. [PMID: 33172030 DOI: 10.3390/cancers12113285] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
392 El Sabbagh R, Azar NS, Eid AA, Azar ST. Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review. Int J Gen Med 2020;13:1003-9. [PMID: 33177863 DOI: 10.2147/IJGM.S261433] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
393 Mulkey F, Theoret MR, Keegan P, Pazdur R, Sridhara R. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. J Immunother Cancer 2020;8:e000146. [PMID: 32107275 DOI: 10.1136/jitc-2019-000146] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
394 Luo H, Ma C, Shao J, Cao J. Prognostic Implications of Novel Ten-Gene Signature in Uveal Melanoma. Front Oncol 2020;10:567512. [PMID: 33194647 DOI: 10.3389/fonc.2020.567512] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
395 White MG, Schulte JJ, Xue L, Berger Y, Schuitevoerder D, Vining CC, Kindler HL, Husain A, Turaga KK, Eng OS. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer 2021;124:564-6. [PMID: 33100328 DOI: 10.1038/s41416-020-01130-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
396 Wang Y, Kong D, Wang C, Chen J, Li J, Liu Z, Li X, Wang Z, Yao G, Wang X. A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials. Technol Cancer Res Treat 2020;19:1533033820967454. [PMID: 33084525 DOI: 10.1177/1533033820967454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
397 Hudson K, Cross N, Jordan-Mahy N, Leyland R. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020;11:568931. [PMID: 33193345 DOI: 10.3389/fimmu.2020.568931] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
398 Awada G, Ben Salama L, De Cremer J, Schwarze JK, Fischbuch L, Seynaeve L, Du Four S, Vanbinst AM, Michotte A, Everaert H, Rogiers A, Theuns P, Duerinck J, Neyns B. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). J Immunother Cancer 2020;8:e001146. [PMID: 33067319 DOI: 10.1136/jitc-2020-001146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
399 Kaumaya PTP, Guo L, Overholser J, Penichet ML, Bekaii-Saab T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology 2020;9:1818437. [PMID: 33117602 DOI: 10.1080/2162402X.2020.1818437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
400 Cheng WY, Wu CY, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut 2020;69:1867-76. [PMID: 32759302 DOI: 10.1136/gutjnl-2020-321153] [Cited by in Crossref: 103] [Cited by in F6Publishing: 99] [Article Influence: 34.3] [Reference Citation Analysis]
401 Bassil C, Khimani F. Immunotherapy use in kidney transplant recipients: Immune checkpoint inhibitors and CAR-T cell therapy. Journal of Onco-Nephrology 2020;4:165-170. [DOI: 10.1177/2399369320953163] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
402 Lee AY, Brady MS. Neoadjuvant immunotherapy for melanoma. J Surg Oncol 2021;123:782-8. [PMID: 33002195 DOI: 10.1002/jso.26229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
403 Chen C, An L, Cheng Y, Luo X, Li Z, Liu X. Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. Front Oncol 2020;10:1404. [PMID: 32983970 DOI: 10.3389/fonc.2020.01404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
404 Procházková I. A long-term survivor female patient with metastatic melanoma after treatment with pembrolizumab in the third line. Onkologie 2020;14:116-118. [DOI: 10.36290/xon.2020.068] [Reference Citation Analysis]
405 Hu W, Wang G, Wang Y, Riese MJ, You M. Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. iScience 2020;23:101580. [PMID: 33083746 DOI: 10.1016/j.isci.2020.101580] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
406 Wei Y, Xiao X, Lao XM, Zheng L, Kuang DM. Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cell Mol Life Sci 2021;78:867-87. [PMID: 32940722 DOI: 10.1007/s00018-020-03637-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
407 Su C, Wang H, Liu Y, Guo Q, Zhang L, Li J, Zhou W, Yan Y, Zhou X, Zhang J. Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. Front Oncol 2020;10:554313. [PMID: 33072580 DOI: 10.3389/fonc.2020.554313] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
408 Taleb B A. Tumour flare reaction in cancer treatments: a comprehensive literature review. Anticancer Drugs 2019;30:953-8. [PMID: 31348010 DOI: 10.1097/CAD.0000000000000814] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
409 Endo F, Akiyama Y, Onishi M, Fujisawa R, Sasaki N, Nikai H, Baba S, Sugimoto R, Kimura T, Takahara T, Iwaya T, Otsuka K, Nitta H, Koeda K, Sugai T, Sasaki A. Primary esophageal malignant melanoma successfully treated with anti-PD-1 antibody for retroperitoneal recurrence after esophagectomy: A case report. Int J Surg Case Rep 2020;75:152-6. [PMID: 32950945 DOI: 10.1016/j.ijscr.2020.09.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
410 Nakazawa Y, Gannichida A, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 2020;46:481-8. [DOI: 10.5649/jjphcs.46.481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
411 Cowey CL, Boyd M, Aguilar KM, Beeks A, Krepler C, Scherrer E. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting. Cancer Med 2020;9:7863-78. [PMID: 32871054 DOI: 10.1002/cam4.3312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
412 Yokohama K, Asai A, Matsui M, Okamoto N, Yasuoka H, Nishikawa T, Ohama H, Tsuchimoto Y, Inoue Y, Fukunishi S, Uchiyama K, Higuchi K. Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. Sci Rep 2020;10:14470. [PMID: 32879383 DOI: 10.1038/s41598-020-71561-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
413 Jiang C, Wallington DG, Anker CJ, Lawson DH, Yushak ML, Kudchadkar RR, Tarhini A, Khan MK. Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases. Neurosurgery 2020;87:498-515. [PMID: 32315430 DOI: 10.1093/neuros/nyaa076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
414 Beyranvand Nejad E, Labrie C, Abdulrahman Z, van Elsas MJ, Rademaker E, Kleinovink JW, van der Sluis TC, van Duikeren S, Teunisse AFAS, Jochemsen AG, Oosting J, de Miranda NFCC, Van Hall T, Arens R, van der Burg SH. Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy. J Immunother Cancer 2020;8:e001326. [PMID: 32873723 DOI: 10.1136/jitc-2020-001326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
415 Kundel Y, Sternschuss M, Moore A, Perl G, Brenner B, Goldvaser H. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis. Cancer Med 2020;9:7613-25. [PMID: 32869544 DOI: 10.1002/cam4.3417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
416 Cybulska-Stopa B, Rogala P, Czarnecka AM, Ługowska I, Teterycz P, Galus Ł, Rajczykowski M, Dawidowska A, Piejko K, Suwiński R, Mackiewicz J, Rutkowski P. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. Adv Med Sci 2020;65:316-23. [PMID: 32554313 DOI: 10.1016/j.advms.2020.05.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
417 Grabovska Y, Mackay A, O'Hare P, Crosier S, Finetti M, Schwalbe EC, Pickles JC, Fairchild AR, Avery A, Cockle J, Hill R, Lindsey J, Hicks D, Kristiansen M, Chalker J, Anderson J, Hargrave D, Jacques TS, Straathof K, Bailey S, Jones C, Clifford SC, Williamson D. Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Nat Commun 2020;11:4324. [PMID: 32859926 DOI: 10.1038/s41467-020-18070-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 13.0] [Reference Citation Analysis]
418 Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ, Ji J. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res 2020;8:35. [PMID: 32864132 DOI: 10.1186/s40364-020-00212-5] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 18.0] [Reference Citation Analysis]
419 Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, Tan C, Wang Y, Catenacci DVT. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. Clin Cancer Res 2020;26:6453-63. [PMID: 32820017 DOI: 10.1158/1078-0432.CCR-20-2085] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
420 Ueki Y, Suzuki M, Horikawa Y, Watanabe H, Yamaguchi Y, Morita C, Tsukada A, Takumida H, Kusaba Y, Katsuno T, Tsujimoto Y, Sakamoto K, Hashimoto M, Terada J, Ishii S, Takasaki J, Naka G, Iikura M, Izumi S, Takeda Y, Hojo M, Sugiyama H. Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer. Thorac Cancer 2020;11:2731-5. [PMID: 32767641 DOI: 10.1111/1759-7714.13582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
421 Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Delli Pizzi A, Lalezari F, Lambregts DMJ, Rohaan MW, Parmar C, Rozeman EA, Hartemink KJ, Swanton C, Haanen JBAG, Blank CU, Smit EF, Beets-Tan RGH, Aerts HJWL. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol 2019;30:998-1004. [PMID: 30895304 DOI: 10.1093/annonc/mdz108] [Cited by in Crossref: 206] [Cited by in F6Publishing: 231] [Article Influence: 68.7] [Reference Citation Analysis]
422 Park HJ, Kim KW, Pyo J, Suh CH, Yoon S, Hatabu H, Nishino M. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Radiology 2020;297:87-96. [PMID: 32749204 DOI: 10.1148/radiol.2020200443] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
423 Ben-aharon O, Magnezi R, Leshno M, Goldstein DA. Mature Versus Registration Studies of Immuno‐Oncology Agents: Does Value Improve With Time? JCO Oncology Practice 2020;16:e779-e790. [DOI: 10.1200/jop.19.00725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
424 Muraki R, Morita Y, Ida S, Kitajima R, Furuhashi S, Kiuchi R, Takeda M, Kikuchi H, Hiramatsu Y, Sakaguchi T, Kasuya A, Hotta Y, Takeuchi H. Multimodal therapy with surgery and adjuvant nivolumab for late-onset multiple liver metastases of choroidal malignant melanoma: a case report. Surg Case Rep 2020;6:187. [PMID: 32737694 DOI: 10.1186/s40792-020-00948-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
425 Cabibbo G, Celsa C, Enea M, Battaglia S, Rizzo GEM, Grimaudo S, Matranga D, Attanasio M, Bruzzi P, Craxì A, Cammà C. Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. Cancers (Basel) 2020;12:E2132. [PMID: 32752060 DOI: 10.3390/cancers12082132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
426 Kuzume A, Chi S, Yamauchi N, Minami Y. Immune-Checkpoint Blockade Therapy in Lymphoma. Int J Mol Sci 2020;21:E5456. [PMID: 32751706 DOI: 10.3390/ijms21155456] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
427 Kuhara Y, Ninomiya M, Hirahara S, Doi H, Kenji S, Toyota K, Yano R, Kobayashi H, Hashimoto Y, Yokoyama Y, Sakashita Y, Miyamoto K. A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect. Int Cancer Conf J 2020;9:193-8. [PMID: 32904110 DOI: 10.1007/s13691-020-00433-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
428 Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, Kawakami H, Tanaka K, Hayashi H, Takeda M, Maeda N, Kagari T, Hirotani K, Tsurutani J, Nishio K, Doi K, Miyazawa M, Nakagawa K. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest 2020;130:374-88. [PMID: 31661465 DOI: 10.1172/JCI126598] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
429 Patel K, Siraj S, Smith C, Nair M, Vishwanatha JK, Basha R. Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy. Crit Rev Oncog 2019;24:105-18. [PMID: 31679206 DOI: 10.1615/CritRevOncog.2019031417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
430 Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel) 2020;9:E34. [PMID: 32698317 DOI: 10.3390/antib9030034] [Cited by in Crossref: 136] [Cited by in F6Publishing: 145] [Article Influence: 45.3] [Reference Citation Analysis]
431 Lau SP, van Montfoort N, Kinderman P, Lukkes M, Klaase L, van Nimwegen M, van Gulijk M, Dumas J, Mustafa DAM, Lievense SLA, Groeneveldt C, Stadhouders R, Li Y, Stubbs A, Marijt KA, Vroman H, van der Burg SH, Aerts J, van Hall T, Dammeijer F, van Eijck CHJ. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. J Immunother Cancer 2020;8:e000772. [PMID: 32690771 DOI: 10.1136/jitc-2020-000772] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
432 Uehara N, Otsuki N, Kubo M, Kitamoto J, Kojima Y, Teshima M, Shinomiya H, Shirakawa T, Nibu KI. Oncolytic effect of Midkine promoter-based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891. Cancer Rep (Hoboken) 2020;3:e1231. [PMID: 32671980 DOI: 10.1002/cnr2.1231] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
433 Liu T, Jin B, Chen J, Wang H, Lin S, Dang J, Li G. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. Ther Adv Med Oncol 2020;12:1758835920940927. [PMID: 32774474 DOI: 10.1177/1758835920940927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
434 Rossi E, Schinzari G, Maiorano BA, Indellicati G, Di Stefani A, Pagliara MM, Fragomeni SM, De Luca EV, Sammarco MG, Garganese G, Galli J, Blasi MA, Paludetti G, Scambia G, Peris K, Tortora G. Efficacy of immune checkpoint inhibitors in different types of melanoma. Hum Vaccin Immunother 2021;17:4-13. [PMID: 32663057 DOI: 10.1080/21645515.2020.1771986] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
435 Dewulf J, Adhikari K, Vangestel C, Wyngaert TVD, Elvas F. Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders-An Update. Cancers (Basel) 2020;12:E1868. [PMID: 32664521 DOI: 10.3390/cancers12071868] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
436 Song P, Zhang D, Cui X, Zhang L. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer 2020;11:2406-30. [PMID: 32643323 DOI: 10.1111/1759-7714.13541] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
437 Loo K, Gauvin G, Soliman I, Renzetti M, Deng M, Ross E, Luo B, Wu H, Reddy S, Olszanski AJ, Farma JM. Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response. Pigment Cell Melanoma Res 2020;33:878-88. [PMID: 32564504 DOI: 10.1111/pcmr.12909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
438 Guo L, Wei R, Lin Y, Kwok HF. Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective. Front Immunol 2020;11:1508. [PMID: 32733486 DOI: 10.3389/fimmu.2020.01508] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
439 Terheyden P, Krackhardt A, Eigentler T. The Systemic Treatment of Melanoma. Dtsch Arztebl Int 2019;116:497-504. [PMID: 31452501 DOI: 10.3238/arztebl.2019.0497] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
440 Zhang CX, Huang DJ, Baloche V, Zhang L, Xu JX, Li BW, Zhao XR, He J, Mai HQ, Chen QY, Zhang XS, Busson P, Cui J, Li J. Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation. Oncogenesis 2020;9:65. [PMID: 32632113 DOI: 10.1038/s41389-020-00248-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
441 Indini A, Di Guardo L, Cimminiello C, Lorusso D, Raspagliesi F, Del Vecchio M. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. J Gynecol Oncol 2019;30:e94. [PMID: 31576688 DOI: 10.3802/jgo.2019.30.e94] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
442 Fujikawa I, Ando T, Suzuki-Karasaki M, Suzuki-Karasaki M, Ochiai T, Suzuki-Karasaki Y. Aspirin Induces Mitochondrial Ca2+ Remodeling in Tumor Cells via ROS‒Depolarization‒Voltage-Gated Ca2+ Entry. Int J Mol Sci 2020;21:E4771. [PMID: 32635638 DOI: 10.3390/ijms21134771] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
443 Chen J, Li S, Yao Q, Du N, Fu X, Lou Y, Wang M, Mao F, Mao D, Khadaroo PA, Tang Y. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. World J Surg Oncol 2020;18:150. [PMID: 32620130 DOI: 10.1186/s12957-020-01933-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
444 Passaro A, Addeo A, Von Garnier C, Blackhall F, Planchard D, Felip E, Dziadziuszko R, de Marinis F, Reck M, Bouchaab H, Peters S. ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open. 2020;5. [PMID: 32581069 DOI: 10.1136/esmoopen-2020-000820] [Cited by in Crossref: 52] [Cited by in F6Publishing: 65] [Article Influence: 17.3] [Reference Citation Analysis]
445 Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA, Spain L, Yousaf N, Hunter N, Eldridge L, Pavlidis P, Irving P, Hayee B, Turajlic S, Larkin J, Lindsay JO, Gore M. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679-97. [PMID: 32553146 DOI: 10.1016/S2468-1253(20)30014-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
446 Zhang J, Shih DJH, Lin SY. Role of DNA repair defects in predicting immunotherapy response. Biomark Res 2020;8:23. [PMID: 32612833 DOI: 10.1186/s40364-020-00202-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
447 Leonardi GC, Candido S, Falzone L, Spandidos DA, Libra M. Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol 2020;57:609-18. [PMID: 32582963 DOI: 10.3892/ijo.2020.5088] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 16.0] [Reference Citation Analysis]
448 Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol 2020;16:1767-91. [PMID: 32564612 DOI: 10.2217/fon-2020-0224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
449 Bunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. Cancer Immunol Immunother 2020;69:2465-76. [PMID: 32556443 DOI: 10.1007/s00262-020-02634-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
450 Shimozaki K, Sukawa Y, Beppu N, Kurihara I, Suzuki S, Mizuno R, Funakoshi T, Ikemura S, Tsugaru K, Togasaki K, Kawasaki K, Hirata K, Hayashi H, Hamamoto Y, Takaishi H, Kanai T. Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. Cancer Manag Res 2020;12:4585-93. [PMID: 32606951 DOI: 10.2147/CMAR.S247554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
451 Gaballa S, Hlaing KM, Mahler N, Moursy S, Ahmed A. A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary. Cureus 2020;12:e8602. [PMID: 32676241 DOI: 10.7759/cureus.8602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
452 Eigentler T. Fortgeschrittenes malignes Melanom: Kernpunkte der aktualisierten Leitlinie. Deutsches Ärzteblatt Online 2020. [DOI: 10.3238/persderma.2020.06.12.01] [Reference Citation Analysis]
453 You W, Shang B, Sun J, Liu X, Su L, Jiang S. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep 2020;44:424-37. [PMID: 32627031 DOI: 10.3892/or.2020.7643] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
454 Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 2020;19:533-52. [PMID: 32528145 DOI: 10.1038/s41573-020-0068-6] [Cited by in Crossref: 279] [Cited by in F6Publishing: 308] [Article Influence: 93.0] [Reference Citation Analysis]
455 Peer CJ, Goldstein DA, Goodell JC, Nguyen R, Figg WD, Ratain MJ. Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Br J Clin Pharmacol 2020;86:1769-77. [PMID: 32424951 DOI: 10.1111/bcp.14369] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
456 Guo X, Li W, Hu J, Zhu EC, Su Q. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:1345-54. [PMID: 32507925 DOI: 10.1007/s00228-020-02903-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
457 Zhao JJ, Wen XZ, Ding Y, Li DD, Zhu BY, Li JJ, Weng DS, Zhang X, Zhang XS. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma. Aging (Albany NY) 2020;12:10663-75. [PMID: 32516130 DOI: 10.18632/aging.103285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
458 Sun D, Guan X, Moran AE, Qian DZ, Schedin P, Adey A, Spellman PT, Xia Z. Phenotype-guided subpopulation identification from single-cell sequencing data.. [DOI: 10.1101/2020.06.05.137240] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
459 Navani V, Graves MC, Bowden NA, Van Der Westhuizen A. Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. Br J Clin Pharmacol 2020;86:1736-52. [PMID: 32384184 DOI: 10.1111/bcp.14352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
460 Okamoto I, Sato H, Tsukahara K. DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Auris Nasus Larynx 2020:S0385-8146(20)30090-0. [PMID: 32507527 DOI: 10.1016/j.anl.2020.02.018] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
461 Shoushtari AN, Bao R, Luke JJ. PD-1 Blockade in Chinese versus Western Patients with Melanoma. Clin Cancer Res 2020;26:4171-3. [PMID: 32487680 DOI: 10.1158/1078-0432.CCR-20-1558] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
462 Banks LB, Sullivan RJ. When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma? Am J Clin Dermatol 2020;21:313-21. [PMID: 32026236 DOI: 10.1007/s40257-020-00506-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
463 Siddiqui MS, Lai ZM, Spain L, Greener V, Turajlic S, Larkin J, Morganstein DL. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. J Endocrinol Invest 2021;44:195-203. [PMID: 32449093 DOI: 10.1007/s40618-020-01297-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
464 Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol 2020;83:1239-53. [PMID: 32461079 DOI: 10.1016/j.jaad.2020.03.131] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 12.7] [Reference Citation Analysis]
465 Norton TD, Tada T, Leibowitz R, van der Heide V, Homann D, Landau NR. Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection. Mol Ther 2020;28:1795-805. [PMID: 32497512 DOI: 10.1016/j.ymthe.2020.05.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
466 Golay J, Andrea AE. Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies (Basel) 2020;9:E17. [PMID: 32443877 DOI: 10.3390/antib9020017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
467 Górniak P, Wasylecka-Juszczyńska M, Ługowska I, Rutkowski P, Polak A, Szydłowski M, Juszczyński P. BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells. Mol Oncol 2020;14:1817-32. [PMID: 32330348 DOI: 10.1002/1878-0261.12695] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
468 Wang YN, Lou DF, Li DY, Jiang W, Dong JY, Gao W, Chen HC. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol Lett 2020;20:611-22. [PMID: 32565986 DOI: 10.3892/ol.2020.11618] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
469 Blankenstein SA, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, van Akkooi ACJ. Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. Cancers (Basel) 2020;12:E1176. [PMID: 32392717 DOI: 10.3390/cancers12051176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
470 Music M, Iafolla M, Soosaipillai A, Batruch I, Prassas I, Pintilie M, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Siu LL, Diamandis EP. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. F1000Res 2020;9:337. [PMID: 33299547 DOI: 10.12688/f1000research.22715.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
471 Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38. [PMID: 32382051 DOI: 10.1038/s41572-020-0160-6] [Cited by in Crossref: 317] [Cited by in F6Publishing: 343] [Article Influence: 105.7] [Reference Citation Analysis]
472 De Luca R, Meraviglia S, Blasi L, Maiorana A, Cicero G. Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients. Curr Oncol 2020;27:e75-80. [PMID: 32489255 DOI: 10.3747/co.27.5293] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
473 Dehno MN, Li Y, Weiher H, Schmidt-Wolf IGH. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer. Int J Mol Sci 2020;21:E3078. [PMID: 32349280 DOI: 10.3390/ijms21093078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
474 Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2021;80:36-48. [PMID: 32327425 DOI: 10.1136/annrheumdis-2020-217139] [Cited by in Crossref: 80] [Cited by in F6Publishing: 89] [Article Influence: 26.7] [Reference Citation Analysis]
475 Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019;30:582-8. [PMID: 30715153 DOI: 10.1093/annonc/mdz011] [Cited by in Crossref: 389] [Cited by in F6Publishing: 412] [Article Influence: 129.7] [Reference Citation Analysis]
476 Schaefer A, Sachpekidis C, Diella F, Doerks A, Kratz AS, Meisel C, Jackson DB, Soldatos TG. Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients. Cancers (Basel) 2020;12:E1008. [PMID: 32325840 DOI: 10.3390/cancers12041008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
477 Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L. Checkpoint Inhibitors. Dtsch Arztebl Int 2019;116:119-26. [PMID: 30940340 DOI: 10.3238/arztebl.2019.0119] [Cited by in Crossref: 34] [Cited by in F6Publishing: 44] [Article Influence: 11.3] [Reference Citation Analysis]
478 Carlson RD, Flickinger JC Jr, Snook AE. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy. Toxins (Basel) 2020;12:E241. [PMID: 32283684 DOI: 10.3390/toxins12040241] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
479 Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol 2021;151:41-53. [PMID: 32253714 DOI: 10.1007/s11060-020-03448-1] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 24.0] [Reference Citation Analysis]
480 Shin MH, Kim J, Lim SA, Kim J, Lee KM. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. Int J Mol Sci 2020;21:E2531. [PMID: 32260561 DOI: 10.3390/ijms21072531] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
481 Furuse M, Kuwabara H, Ikeda N, Hattori Y, Ichikawa T, Kagawa N, Kikuta K, Tamai S, Nakada M, Wakabayashi T, Wanibuchi M, Kuroiwa T, Hirose Y, Miyatake SI. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer 2020;20:277. [PMID: 32248797 DOI: 10.1186/s12885-020-06755-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
482 Tran CN, Abu-sbeih H, Luo W, Lu Y, Wang Y. Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. Journal of Immunotherapy and Precision Oncology 2019;2:40-5. [DOI: 10.4103/jipo.jipo_18_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
483 Nomura M, Nagatomo R, Doi K, Shimizu J, Baba K, Saito T, Matsumoto S, Inoue K, Muto M. Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors.JAMA Netw Open. 2020;3:e202895. [PMID: 32297948 DOI: 10.1001/jamanetworkopen.2020.2895] [Cited by in Crossref: 86] [Cited by in F6Publishing: 95] [Article Influence: 28.7] [Reference Citation Analysis]
484 Fromer MW, Scoggins CR. Article Commentary: Cancer Immunotherapy for the General Surgeon. The American Surgeon 2020;86:284-292. [DOI: 10.1177/000313482008600423] [Reference Citation Analysis]
485 Mäkelä S, Kohtamäki L, Laukka M, Juteau S, Hernberg M. Limited-duration anti-PD-1 therapy for patients with metastatic melanoma. Acta Oncol 2020;59:438-43. [PMID: 32000554 DOI: 10.1080/0284186X.2020.1716388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
486 Aversa I, Malanga D, Fiume G, Palmieri C. Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy. Int J Mol Sci 2020;21:E2378. [PMID: 32235561 DOI: 10.3390/ijms21072378] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
487 Maggio I, Manuzzi L, Lamberti G, Ricci AD, Tober N, Campana D. Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. Cancers (Basel) 2020;12:E832. [PMID: 32235636 DOI: 10.3390/cancers12040832] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
488 Lu JE, Chang JR, Berry JL, In GK, Zhang-Nunes S. Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma. Int Ophthalmol Clin 2020;60:77-89. [PMID: 32205655 DOI: 10.1097/IIO.0000000000000308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
489 Mitra S, Lauss M, Cabrita R, Choi J, Zhang T, Isaksson K, Olsson H, Ingvar C, Carneiro A, Staaf J, Ringnér M, Nielsen K, Brown KM, Jönsson G. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. Mol Oncol 2020;14:933-50. [PMID: 32147909 DOI: 10.1002/1878-0261.12663] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
490 Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel) 2020;12:E738. [PMID: 32245016 DOI: 10.3390/cancers12030738] [Cited by in Crossref: 498] [Cited by in F6Publishing: 532] [Article Influence: 166.0] [Reference Citation Analysis]
491 Wunder JS, Lee MJ, Nam J, Lau BY, Dickson BC, Pinnaduwage D, Bull SB, Ferguson PC, Seto A, Gokgoz N, Andrulis IL. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. Oncoimmunology 2020;9:1737385. [PMID: 33457085 DOI: 10.1080/2162402X.2020.1737385] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
492 Na'ara S, Mukherjee A, Billan S, Gil Z. Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma. Onco Targets Ther 2020;13:2289-98. [PMID: 32214828 DOI: 10.2147/OTT.S182580] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
493 Hromic-Jahjefendic A, Lundstrom K. Viral Vector-Based Melanoma Gene Therapy. Biomedicines 2020;8:E60. [PMID: 32187995 DOI: 10.3390/biomedicines8030060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
494 Moody R, Wilson K, Jaworowski A, Plebanski M. Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells. Cancers (Basel) 2020;12:E673. [PMID: 32183059 DOI: 10.3390/cancers12030673] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
495 Jiang Y, Zhao X, Fu J, Wang H. Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. Front Immunol 2020;11:339. [PMID: 32226426 DOI: 10.3389/fimmu.2020.00339] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 14.3] [Reference Citation Analysis]
496 Hill SL, Johnson PW. elearning for cancer immunotherapy. Ecancermedicalscience 2020;14:ed94. [PMID: 32153657 DOI: 10.3332/ecancer.2020.ed94] [Reference Citation Analysis]
497 Liu Y, Wu W. Cardiovascular immune-related adverse events: Evaluation, diagnosis and management. Asia Pac J Clin Oncol 2020;16:232-40. [PMID: 32129935 DOI: 10.1111/ajco.13326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
498 Chang CY, Park H, Malone DC, Wang CY, Wilson DL, Yeh YM, Van Boemmel-Wegmann S, Lo-Ciganic WH. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis. JAMA Netw Open 2020;3:e201611. [PMID: 32211869 DOI: 10.1001/jamanetworkopen.2020.1611] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
499 Kang TH, Jung ST. Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer. Biomolecules 2020;10:E382. [PMID: 32121592 DOI: 10.3390/biom10030382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
500 Lee CH, Cho J, Lee K. Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment. Biomol Ther (Seoul) 2020;28:119-30. [PMID: 31739382 DOI: 10.4062/biomolther.2019.135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
501 Tian Y, Zhang Z, Yang X, Li D, Zhang L, Li Z, Zhang S, Mao Y, Jin C, Zhao Y. The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:261. [PMID: 32181158 DOI: 10.3389/fonc.2020.00261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
502 Forschner A, Hilke FJ, Bonzheim I, Gschwind A, Demidov G, Amaral T, Ossowski S, Riess O, Schroeder C, Martus P, Klumpp B, Gonzalez-Menendez I, Garbe C, Niessner H, Sinnberg T. MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. Cancers (Basel) 2020;12:E540. [PMID: 32110946 DOI: 10.3390/cancers12030540] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
503 Ou A, Sumrall A, Phuphanich S, Spetzler D, Gatalica Z, Xiu J, Michelhaugh S, Brenner A, Pandey M, Kesari S, Korn WM, Mittal S, Westin J, Heimberger AB. Primary CNS lymphoma commonly expresses immune response biomarkers. Neurooncol Adv 2020;2:vdaa018. [PMID: 32201861 DOI: 10.1093/noajnl/vdaa018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
504 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Mol Med Rep 2020;21:1849-60. [PMID: 32319631 DOI: 10.3892/mmr.2020.10991] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
505 Martin-Romano P, Castanon E, Ammari S, Champiat S, Hollebecque A, Postel-Vinay S, Baldini C, Varga A, Michot JM, Vuagnat P, Marabelle A, Soria JC, Ferté C, Massard C. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Med 2020;9:2643-52. [PMID: 32074405 DOI: 10.1002/cam4.2797] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
506 Tang G, Yin W. Development of an Immune Infiltration-Related Prognostic Scoring System Based on the Genomic Landscape Analysis of Glioblastoma Multiforme. Front Oncol 2020;10:154. [PMID: 32133292 DOI: 10.3389/fonc.2020.00154] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
507 Kakkassery V, Emmert S, Adamietz IA, Kovács G, Jünemann AM, Otte C, Zimbelmann M, Brosig A, Grisanti S, Heindl LM. [Alternative treatment options for periorbital basal cell carcinoma]. Ophthalmologe 2020;117:113-23. [PMID: 31811367 DOI: 10.1007/s00347-019-01021-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
508 Linxweiler M, Kuo F, Katabi N, Lee M, Nadeem Z, Dalin MG, Makarov V, Chowell D, Dogan S, Ganly I, Hakimi AA, Wong RJ, Riaz N, Ho AL, Chan TA, Morris LGT. The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. Clin Cancer Res 2020;26:2859-70. [PMID: 32060100 DOI: 10.1158/1078-0432.CCR-19-3758] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
509 Kottschade LA, Yan Y. Atypical Presentations and Management of Endocrine and Hepatic Immune-Related Adverse Events From Adjuvant Immune Checkpoint Inhibitor Therapy in Stage III Resected Melanoma. JCO Oncol Pract 2020;16:10s-4s. [PMID: 32045536 DOI: 10.1200/JOP.19.00649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
510 Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:91. [PMID: 32117745 DOI: 10.3389/fonc.2020.00091] [Cited by in Crossref: 55] [Cited by in F6Publishing: 62] [Article Influence: 18.3] [Reference Citation Analysis]
511 Saab S, Zalzale H, Rahal Z, Khalifeh Y, Sinjab A, Kadara H. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Front Immunol 2020;11:159. [PMID: 32117295 DOI: 10.3389/fimmu.2020.00159] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
512 Kasanen H, Hernberg M, Mäkelä S, Brück O, Juteau S, Kohtamäki L, Ilander M, Mustjoki S, Kreutzman A. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. Cancer Immunol Immunother 2020;69:717-30. [PMID: 32036449 DOI: 10.1007/s00262-020-02497-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
513 Sun L, Zhang L, Yu J, Zhang Y, Pang X, Ma C, Shen M, Ruan S, Wasan HS, Qiu S. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep 2020;10:2083. [PMID: 32034198 DOI: 10.1038/s41598-020-58674-4] [Cited by in Crossref: 73] [Cited by in F6Publishing: 79] [Article Influence: 24.3] [Reference Citation Analysis]
514 Zhao B, Zhao H, Zhao J. Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. Ther Adv Med Oncol 2020;12:1758835919895753. [PMID: 32082425 DOI: 10.1177/1758835919895753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
515 Palmer AC, Izar B, Hwangbo H, Sorger PK. Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors.. [DOI: 10.1101/2020.01.31.20019604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
516 Rizk EM, Seffens AM, Trager MH, Moore MR, Geskin LJ, Gartrell-Corrado RD, Wong W, Saenger YM. Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. Am J Clin Dermatol 2020;21:1-11. [PMID: 31602560 DOI: 10.1007/s40257-019-00475-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
517 Friedlander P. Advances in the Systemic Treatment of Melanoma Brain Metastases. Brain and Spinal Tumors - Primary and Secondary 2020. [DOI: 10.5772/intechopen.85673] [Reference Citation Analysis]
518 Xie C, Duffy AG, Brar G, Fioravanti S, Mabry-Hrones D, Walker M, Bonilla CM, Wood BJ, Citrin DE, Gil Ramirez EM, Escorcia FE, Redd B, Hernandez JM, Davis JL, Gasmi B, Kleiner D, Steinberg SM, Jones JC, Greten TF. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:2318-26. [PMID: 31996388 DOI: 10.1158/1078-0432.CCR-19-3624] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
519 Hall E, Zhang J, Kim EJ, Hwang G, Chu G, Bhatia S, Reddy S. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Med 2020;9:2106-12. [PMID: 31994335 DOI: 10.1002/cam4.2888] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
520 Faury S, Foucaud J. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. PLoS One 2020;15:e0227344. [PMID: 31978145 DOI: 10.1371/journal.pone.0227344] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
521 Akiyama M, Matsuda Y, Arai T, Saeki H. PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract. Oncol Lett 2020;19:2481-8. [PMID: 32194748 DOI: 10.3892/ol.2020.11325] [Reference Citation Analysis]
522 Xiao Q, Nobre A, Piñeiro P, Berciano-Guerrero MÁ, Alba E, Cobo M, Lauschke VM, Barragán I. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. J Clin Med 2020;9:E286. [PMID: 31968651 DOI: 10.3390/jcm9010286] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
523 Mir T, Al-Masalmeh N, Ambreen S. Acute Pneumonitis Due to Nivolumab and Ipilimumab Combination. Am J Ther 2020;29:e126-8. [PMID: 31972571 DOI: 10.1097/MJT.0000000000001139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
524 Kanaya N, Kuroda S, Kakiuchi Y, Kumon K, Tsumura T, Hashimoto M, Morihiro T, Kubota T, Aoyama K, Kikuchi S, Nishizaki M, Kagawa S, Tazawa H, Mizuguchi H, Urata Y, Fujiwara T. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Mol Ther 2020;28:794-804. [PMID: 31991110 DOI: 10.1016/j.ymthe.2020.01.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
525 Marquardt JU, Saborowski A, Czauderna C, Vogel A. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. Target Oncol. 2019;14:115-123. [PMID: 30805831 DOI: 10.1007/s11523-019-00624-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
526 Persigehl T, Lennartz S, Schwartz LH. iRECIST: how to do it. Cancer Imaging. 2020;20:2. [PMID: 31900236 DOI: 10.1186/s40644-019-0281-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
527 Zhao L, Yu J, Wang J, Li H, Che J, Cao B. Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. J Cancer 2020;11:41-50. [PMID: 31892971 DOI: 10.7150/jca.32724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
528 Rapisuwon S, Qin Y, Roszik J, Carapeto F, Patel S, Carvajal RD. Systemic Therapy for Mucosal, Acral, and Uveal Melanoma. Cutaneous Melanoma 2020. [DOI: 10.1007/978-3-030-05070-2_62] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
529 Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020;20:651-68. [PMID: 32433532 DOI: 10.1038/s41577-020-0306-5] [Cited by in Crossref: 1139] [Cited by in F6Publishing: 1134] [Article Influence: 379.7] [Reference Citation Analysis]
530 Li W, Qie J, Zhang Y, Chang J. Spatiotemporal Changes in Checkpoint Molecule Expression. Adv Exp Med Biol 2020;1248:167-200. [PMID: 32185711 DOI: 10.1007/978-981-15-3266-5_8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
531 Aryan Z, Keshavarz-fathi M, Mellstedt H, Rezaei N. Cancer Immunotherapy Confers a Global Benefit. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-57949-4_1] [Reference Citation Analysis]
532 Wicki A. Metabolische und endokrine Toxizität antineoplastischer Substanzen. Springer Reference Medizin 2020. [DOI: 10.1007/978-3-662-46764-0_284-1] [Reference Citation Analysis]
533 Shi H, Lan J, Yang J. Mechanisms of Resistance to Checkpoint Blockade Therapy. Adv Exp Med Biol 2020;1248:83-117. [PMID: 32185708 DOI: 10.1007/978-981-15-3266-5_5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
534 Guisier F, Barros-Filho MC, Rock LD, Strachan-Whaley M, Marshall EA, Dellaire G, Lam WL. Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment. Adv Exp Med Biol 2020;1224:35-51. [PMID: 32036603 DOI: 10.1007/978-3-030-35723-8_3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
535 Paschen A, Schadendorf D. The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. Recent Results Cancer Res 2020;214:169-87. [PMID: 31473853 DOI: 10.1007/978-3-030-23765-3_6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
536 Ascierto PA, Atkins MB. Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. Cutaneous Melanoma 2020. [DOI: 10.1007/978-3-030-05070-2_61] [Reference Citation Analysis]
537 Covelli AM, Min H, Mccready DR, Look Hong NJ, Lipa JE, Petrella TM, Wright FC. Melanoma. Surgical Oncology Manual 2020. [DOI: 10.1007/978-3-030-48363-0_16] [Reference Citation Analysis]
538 Luciani A. Principles of Cancer Targeted Therapy in Older Adults. Geriatric Oncology 2020. [DOI: 10.1007/978-3-319-57415-8_16] [Reference Citation Analysis]
539 Kabacaoglu D, Ruess DA, Algül H. Targeting the Immune System in Pancreatic Cancer. Translational Pancreatic Cancer Research 2020. [DOI: 10.1007/978-3-030-49476-6_14] [Reference Citation Analysis]
540 Lopci E, Castello A. CNS Tumors: PET/CT and MRI for Response Assessment of CNS Tumors Following Immunotherapy. Atlas of Response to Immunotherapy 2020. [DOI: 10.1007/978-3-030-31113-1_3] [Reference Citation Analysis]
541 Mitchell TC, Karakousis G, Schuchter L. Melanoma. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00066-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
542 Pavlick A, Weber J. Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. Cutaneous Melanoma 2020. [DOI: 10.1007/978-3-030-05070-2_60] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
543 Medikonda R, Lim M. Immunotherapy and Radiosurgery. CyberKnife NeuroRadiosurgery 2020. [DOI: 10.1007/978-3-030-50668-1_37] [Reference Citation Analysis]
544 Dobrenkov K, Cheung NV. Therapeutic Antibodies and Immunologic Conjugates. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00030-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
545 Goto H, Sugita K, Yamamoto O. Expression of Programmed Death-Ligand 1 in Cutaneous Squamous Cell Carcinoma Arising in Sun-Exposed and Nonsun-Exposed Skin. Indian J Dermatol 2020;65:506-9. [PMID: 33487707 DOI: 10.4103/ijd.IJD_187_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
546 Gogas H, Diamantopoulos P, Polyzos A. Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. Non-Melanoma Skin Cancer and Cutaneous Melanoma 2020. [DOI: 10.1007/978-3-030-18797-2_2] [Reference Citation Analysis]
547 Friedlander P, Simpson W, Cajulis C. Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. Image Guided Dermatologic Treatments 2020. [DOI: 10.1007/978-3-030-29236-2_6] [Reference Citation Analysis]
548 D'Andrea MA, Reddy GK. Extracranial systemic antitumor response through the abscopal effect induced by brain radiation in a patient with metastatic melanoma. Radiat Oncol J. 2019;37:302-308. [PMID: 31918469 DOI: 10.3857/roj.2019.00437] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
549 Mina LA, Lim S, Bahadur SW, Firoz AT. Immunotherapy for the Treatment of Breast Cancer: Emerging New Data. Breast Cancer (Dove Med Press) 2019;11:321-8. [PMID: 32099454 DOI: 10.2147/BCTT.S184710] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
550 Cembrola B, Ruzza V, Troise F, Esposito ML, Sasso E, Cafaro V, Passariello M, Visconte F, Raia M, Del Vecchio L, D'Alise AM, Cortese R, Scarselli E, Zambrano N, De Lorenzo C, Nicosia A. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. Biomed Res Int 2019;2019:6051870. [PMID: 31976323 DOI: 10.1155/2019/6051870] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
551 Jiang X, Liu G, Li Y, Pan Y. Immune checkpoint: The novel target for antitumor therapy. Genes Dis 2021;8:25-37. [PMID: 33569511 DOI: 10.1016/j.gendis.2019.12.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
552 Houghton PJ, Kurmasheva RT. Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacol Rev 2019;71:671-97. [PMID: 31558580 DOI: 10.1124/pr.118.016972] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
553 Chen R, Chen Y, Huang G, Liu J. Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer. Aging (Albany NY) 2019;11:12270-7. [PMID: 31848322 DOI: 10.18632/aging.102567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
554 Nikolaou M, Nikolaou G, Digklia A, Pontas C, Tsoukalas N, Kyrgias G, Tolia M. Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. Integr Cancer Ther 2019;18:1534735419827090. [PMID: 30791740 DOI: 10.1177/1534735419827090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
555 Lu J, Yang J, Liang Y, Meng H, Zhao J, Zhang X. Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. Front Pharmacol 2019;10:1453. [PMID: 31920646 DOI: 10.3389/fphar.2019.01453] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
556 Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol 2019;5:187-94. [PMID: 30422243 DOI: 10.1001/jamaoncol.2018.4514] [Cited by in Crossref: 191] [Cited by in F6Publishing: 202] [Article Influence: 47.8] [Reference Citation Analysis]
557 Xing P, Zhang F, Wang G, Xu Y, Li C, Wang S, Guo Y, Cai S, Wang Y, Li J. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer 2019;7:341. [PMID: 31801636 DOI: 10.1186/s40425-019-0779-6] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 20.5] [Reference Citation Analysis]
558 Pillonel V, Dunet V, Hottinger AF, Berthod G, Schiappacasse L, Peters S, Michielin O, Aedo-Lopez V. Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. J Immunother Cancer 2019;7:336. [PMID: 31791418 DOI: 10.1186/s40425-019-0818-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
559 Hong Y, Ding ZY. PD-1 Inhibitors in the Advanced Esophageal Cancer. Front Pharmacol 2019;10:1418. [PMID: 31920637 DOI: 10.3389/fphar.2019.01418] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
560 Zhou Y, Zhu Y, Xie Y, Ma X. The Role of Long Non-coding RNAs in Immunotherapy Resistance. Front Oncol 2019;9:1292. [PMID: 31850199 DOI: 10.3389/fonc.2019.01292] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
561 Fayne RA, Macedo FI, Rodgers SE, Möller MG. Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. Oncol Rev 2019;13:433. [PMID: 31857858 DOI: 10.4081/oncol.2019.433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
562 Pan PC, Haggiagi A. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. Curr Oncol Rep 2019;21:108. [PMID: 31776691 DOI: 10.1007/s11912-019-0859-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
563 Patel JJ, Levy DA, Nguyen SA, Knochelmann HM, Day TA. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis. Head Neck 2020;42:774-86. [PMID: 31762164 DOI: 10.1002/hed.26036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
564 Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist 2020;25:e398-404. [PMID: 32162817 DOI: 10.1634/theoncologist.2018-0883] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
565 Simeone E, Grimaldi AM, Festino L, Trojaniello C, Vitale MG, Vanella V, Palla M, Ascierto PA. Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. Melanoma Manag 2019;6:MMT30. [PMID: 31871619 DOI: 10.2217/mmt-2019-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
566 Huang PW, Chang JW. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J 2019;42:299-306. [PMID: 31783990 DOI: 10.1016/j.bj.2019.09.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
567 Yatim A, Bohelay G, Grootenboer-Mignot S, Prost-Squarcioni C, Alexandre M, Le Roux-Villet C, Martin A, Maubec E, Caux F. Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. Front Med (Lausanne) 2019;6:249. [PMID: 31750309 DOI: 10.3389/fmed.2019.00249] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
568 Zhang L, Liu Z, Li J, Huang T, Wang Y, Chang L, Zheng W, Ma Y, Chen F, Gong X, Yuan Q, Teaw S, Fang X, Song T, Huo L, Li X, Xia X, Liu Z, Wu J. Genomic analysis of primary and recurrent gliomas reveals clinical outcome related molecular features. Sci Rep 2019;9:16058. [PMID: 31690770 DOI: 10.1038/s41598-019-52515-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
569 Lu J, Li L, Lan Y, Liang Y, Meng H. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. Cancer Med. 2019;8:7503-7515. [PMID: 31679184 DOI: 10.1002/cam4.2661] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
570 Gamboa AC, Lowe M, Yushak ML, Delman KA. Surgical Considerations and Systemic Therapy of Melanoma. Surg Clin North Am 2020;100:141-59. [PMID: 31753109 DOI: 10.1016/j.suc.2019.09.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
571 Pagni F, Guerini-Rocco E, Schultheis AM, Grazia G, Rijavec E, Ghidini M, Lopez G, Venetis K, Croci GA, Malapelle U, Fusco N. Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. Int J Mol Sci 2019;20:E5452. [PMID: 31683784 DOI: 10.3390/ijms20215452] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
572 Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, Sundararajan S. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies (Basel) 2019;8:E51. [PMID: 31640266 DOI: 10.3390/antib8040051] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
573 Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019;19:974. [PMID: 31638948 DOI: 10.1186/s12885-019-6150-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 78] [Article Influence: 17.5] [Reference Citation Analysis]
574 Wu M, Wang Y, Xu Y, Zhu J, Lv C, Sun M, Guo R, Xia Y, Zhang W, Xue C. Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. J Cancer 2019;10:6114-23. [PMID: 31762821 DOI: 10.7150/jca.32638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
575 Billon E, Walz J, Brunelle S, Thomassin J, Salem N, Guerin M, Vicier C, Dermeche S, Albiges L, Tantot F, Nenan S, Pignot G, Gravis G. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma. Front Oncol 2019;9:1033. [PMID: 31649889 DOI: 10.3389/fonc.2019.01033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
576 Lu KL, Wu MY, Wang CH, Wang CW, Hung SI, Chung WH, Chen CB. The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus. Cells 2019;8:E1213. [PMID: 31597242 DOI: 10.3390/cells8101213] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
577 Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A, Vieni S, Gori S, Bazan V, Russo A. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Adv Ther 2019;36:2600-17. [PMID: 31432460 DOI: 10.1007/s12325-019-01057-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 13.5] [Reference Citation Analysis]
578 Huang YF, Xie WJ, Fan HY, Du J. Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. Front Oncol 2019;9:972. [PMID: 31632907 DOI: 10.3389/fonc.2019.00972] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
579 Zhao L, Yang Y, Ma B, Li W, Li T, Han L, Zhang Y, Shang YM, Lin H, Gao Q. Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. J Oncol 2019;2019:6454989. [PMID: 31662753 DOI: 10.1155/2019/6454989] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
580 Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol 2018;4:717-21. [PMID: 29423503 DOI: 10.1001/jamaoncol.2017.5332] [Cited by in Crossref: 151] [Cited by in F6Publishing: 165] [Article Influence: 37.8] [Reference Citation Analysis]
581 Deng S, Yang Q, Shu X, Lang J, Lu S. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2019;10:1063. [PMID: 31607917 DOI: 10.3389/fphar.2019.01063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
582 Du Z, Lin JR, Rashid R, Maliga Z, Wang S, Aster JC, Izar B, Sorger PK, Santagata S. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nat Protoc 2019;14:2900-30. [PMID: 31534232 DOI: 10.1038/s41596-019-0206-y] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 13.5] [Reference Citation Analysis]
583 Lim I, Lindenberg ML, Mena E, Verdini N, Shih JH, Mayfield C, Thompson R, Lin J, Vega A, Mallek M, Cadena J, Diaz C, Mortazavi A, Knopp M, Wright C, Stein M, Pal S, Choyke PL, Apolo AB. 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. Eur J Nucl Med Mol Imaging 2020;47:178-84. [PMID: 31522271 DOI: 10.1007/s00259-019-04483-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
584 Pourhassan HZ, Tryon D, Schaeffer B, Mirshahidi H, Wong J. Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma. Exp Hematol Oncol 2019;8:20. [PMID: 31516766 DOI: 10.1186/s40164-019-0140-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
585 Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M, Lee CK. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:522-8. [PMID: 29470579 DOI: 10.1001/jamaoncol.2017.5236] [Cited by in Crossref: 53] [Cited by in F6Publishing: 61] [Article Influence: 13.3] [Reference Citation Analysis]
586 Ben-Aharon O, Magnezi R, Leshno M, Goldstein DA. Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. JAMA Oncol 2018;4:326-32. [PMID: 29285547 DOI: 10.1001/jamaoncol.2017.4445] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
587 Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World J Gastrointest Pathophysiol 2019; 10(2): 17-28 [PMID: 31559106 DOI: 10.4291/wjgp.v10.i2.17] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
588 Hsu C, Marshall JL, He AR. Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment. Oncologist. 2020;25:105-111. [PMID: 32043797 DOI: 10.1634/theoncologist.2018-0162] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
589 Hori R, Shinohara S, Kojima T, Kagoshima H, Kitamura M, Tateya I, Tamaki H, Kumabe Y, Asato R, Harada H, Kitani Y, Tsujimura T, Honda K, Ichimaru K, Omori K. Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. Cancers (Basel) 2019;11:E1317. [PMID: 31500103 DOI: 10.3390/cancers11091317] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
590 Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4:173-182. [PMID: 28973656 DOI: 10.1001/jamaoncol.2017.3064] [Cited by in Crossref: 493] [Cited by in F6Publishing: 533] [Article Influence: 123.3] [Reference Citation Analysis]
591 Pönisch W, Alten R, Baerwald C. [Autoimmune reactions to immune checkpoint inhibitors]. Z Rheumatol 2017;76:57-62. [PMID: 29330759 DOI: 10.1007/s00393-017-0368-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
592 Kim HJ, Chang JS, Roh MR, Oh BH, Chung KY, Shin SJ, Koom WS. Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients. Front Oncol 2019;9:835. [PMID: 31552171 DOI: 10.3389/fonc.2019.00835] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
593 Tamura K, Hasegawa K, Katsumata N, Matsumoto K, Mukai H, Takahashi S, Nomura H, Minami H. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. Cancer Sci 2019;110:2894-904. [PMID: 31348579 DOI: 10.1111/cas.14148] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 8.3] [Reference Citation Analysis]
594 Clarke JM, George DJ, Lisi S, Salama AKS. Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. Target Oncol 2018;13:1-20. [PMID: 29441437 DOI: 10.1007/s11523-017-0549-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
595 Chat V, Ferguson R, Kirchhoff T. Germline genetic host factors as predictive biomarkers in immuno-oncology. Immuno-Oncology and Technology 2019;2:14-21. [DOI: 10.1016/j.iotech.2019.08.001] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
596 Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz CD, Kudo M. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol 2019;71:543-52. [PMID: 31176752 DOI: 10.1016/j.jhep.2019.05.014] [Cited by in Crossref: 128] [Cited by in F6Publishing: 127] [Article Influence: 32.0] [Reference Citation Analysis]
597 Kamińska-Winciorek G, Cybulska-Stopa B, Lugowska I, Ziobro M, Rutkowski P. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. Postepy Dermatol Alergol 2019;36:382-91. [PMID: 31616210 DOI: 10.5114/ada.2018.80272] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
598 Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R, Ferris RL, Sarkar SN, Thorne SH, Delgoffe GM. Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity 2019;51:548-560.e4. [PMID: 31471106 DOI: 10.1016/j.immuni.2019.07.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 14.8] [Reference Citation Analysis]
599 Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ. Organoid Modeling of the Tumor Immune Microenvironment. Cell 2018;175:1972-1988.e16. [PMID: 30550791 DOI: 10.1016/j.cell.2018.11.021] [Cited by in Crossref: 542] [Cited by in F6Publishing: 565] [Article Influence: 135.5] [Reference Citation Analysis]
600 Varricchi G, Loffredo S, Marone G, Modestino L, Fallahi P, Ferrari SM, de Paulis A, Antonelli A, Galdiero MR. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. Int J Mol Sci 2019;20:E3934. [PMID: 31412566 DOI: 10.3390/ijms20163934] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
601 Galuppini F, Dal Pozzo CA, Deckert J, Loupakis F, Fassan M, Baffa R. Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell Int 2019;19:209. [PMID: 31406485 DOI: 10.1186/s12935-019-0929-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 18.5] [Reference Citation Analysis]
602 Wei H, Jiang H, Song B. Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction. Cancer Med 2019;8:5399-413. [PMID: 31385454 DOI: 10.1002/cam4.2464] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
603 Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, Scutti JB, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P. Characterization and Comparison of GITR Expression in Solid Tumors. Clin Cancer Res 2019;25:6501-10. [PMID: 31358539 DOI: 10.1158/1078-0432.CCR-19-0289] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
604 Rossi E, Schinzari G, Zizzari IG, Maiorano BA, Pagliara MM, Sammarco MG, Fiorentino V, Petrone G, Cassano A, Rindi G, Bria E, Blasi MA, Nuti M, Tortora G. Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy? Cancers (Basel) 2019;11:E1055. [PMID: 31357439 DOI: 10.3390/cancers11081055] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
605 Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. J Immunother Cancer 2019;7:194. [PMID: 31337426 DOI: 10.1186/s40425-019-0675-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
606 Hoefsmit EP, Rozeman EA, Haanen JBAG, Blank CU. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO Open 2019;4:e000472. [PMID: 31423333 DOI: 10.1136/esmoopen-2018-000472] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
607 Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop EO, Debets R, Joerger M, Odink A, van der Veldt AAM, van der Leest CH, Aerts JGJV, Mathijssen RHJ, Koolen SLW. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 2019;7:192. [PMID: 31324223 DOI: 10.1186/s40425-019-0669-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
608 Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, Biskup S. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. J Immunother Cancer 2019;7:180. [PMID: 31300034 DOI: 10.1186/s40425-019-0659-0] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 22.0] [Reference Citation Analysis]
609 Giunta EF, Argenziano G, Brancaccio G, Martinelli E, Ciardiello F, Troiani T. Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment. CCTR 2019;15:110-119. [DOI: 10.2174/1573394714666180927095650] [Reference Citation Analysis]
610 Lamichhane P, Deshmukh R, Brown JA, Jakubski S, Parajuli P, Nolan T, Raja D, Badawy M, Yoon T, Zmiyiwsky M, Lamichhane N. Novel Delivery Systems for Checkpoint Inhibitors. Medicines (Basel) 2019;6:E74. [PMID: 31373327 DOI: 10.3390/medicines6030074] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
611 Sternschein R, Moll M, Ng J, D'Ambrosio C. Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features. Am J Respir Crit Care Med 2018;198:951-3. [PMID: 30095979 DOI: 10.1164/rccm.201803-0525RR] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
612 Potluri R, Ranjan S, Bhandari H, Johnson H, Moshyk A, Kotapati S. Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma. Exp Hematol Oncol 2019;8:14. [PMID: 31312536 DOI: 10.1186/s40164-019-0138-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
613 Yang J, He X, Lv Q, Jing J, Shi H. Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Front Pharmacol 2019;10:726. [PMID: 31312140 DOI: 10.3389/fphar.2019.00726] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
614 Andrechak JC, Dooling LJ, Discher DE. The macrophage checkpoint CD47 : SIRPα for recognition of 'self' cells: from clinical trials of blocking antibodies to mechanobiological fundamentals. Philos Trans R Soc Lond B Biol Sci 2019;374:20180217. [PMID: 31431181 DOI: 10.1098/rstb.2018.0217] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
615 Bostel T, Förster R, Schlampp I, Sprave T, Akbaba S, Wollschläger D, Debus J, Mayer A, Schmidberger H, Rief H, Nicolay NH. Stability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy : Results from a large multicenter cohort. Strahlenther Onkol 2019;195:1074-85. [PMID: 31240346 DOI: 10.1007/s00066-019-01482-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
616 Wada-Ohno M, Ito T, Furue M. Adjuvant Therapy for Melanoma. Curr Treat Options Oncol 2019;20:63. [PMID: 31236710 DOI: 10.1007/s11864-019-0666-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
617 Hashimoto T, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima K, Morii E, Mori M, Doki Y. Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus. Oncol Lett 2019;18:1872-80. [PMID: 31423256 DOI: 10.3892/ol.2019.10519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
618 Connolly C, Bambhania K, Naidoo J. Immune-Related Adverse Events: A Case-Based Approach. Front Oncol 2019;9:530. [PMID: 31293970 DOI: 10.3389/fonc.2019.00530] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
619 Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Front Immunol 2019;10:1337. [PMID: 31258527 DOI: 10.3389/fimmu.2019.01337] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 16.0] [Reference Citation Analysis]
620 Ghahremanloo A, Soltani A, Modaresi SMS, Hashemy SI. Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol (Dordr) 2019;42:609-26. [PMID: 31201647 DOI: 10.1007/s13402-019-00456-w] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
621 Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019;38:255. [PMID: 31196207 DOI: 10.1186/s13046-019-1259-z] [Cited by in Crossref: 345] [Cited by in F6Publishing: 362] [Article Influence: 86.3] [Reference Citation Analysis]
622 Kotsakis A, Kallergi G, Aggouraki D, Lyristi Z, Koinis F, Lagoudaki E, Koutsopoulos A, Georgoulias V, Vetsika EK. CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance? Ther Adv Med Oncol 2019;11:1758835919853193. [PMID: 31217824 DOI: 10.1177/1758835919853193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
623 Gu L, Khadaroo PA, Su H, Kong L, Chen L, Wang X, Li X, Zhu H, Zhong X, Pan J, Chen M. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. BMC Cancer 2019;19:559. [PMID: 31182049 DOI: 10.1186/s12885-019-5785-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
624 Zhang L, Jones-O'Connor M, Awadalla M, Zlotoff DA, Thavendiranathan P, Groarke JD, Villani AC, Lyon AR, Neilan TG. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Treat Options Cardiovasc Med 2019;21:32. [PMID: 31175469 DOI: 10.1007/s11936-019-0731-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
625 Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 2019;7:145. [PMID: 31171039 DOI: 10.1186/s40425-019-0623-z] [Cited by in Crossref: 169] [Cited by in F6Publishing: 179] [Article Influence: 42.3] [Reference Citation Analysis]
626 Rahim MN, Liberal R, Miquel R, Heaton ND, Heneghan MA. Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation? Liver Transpl 2019;25:946-59. [PMID: 30900368 DOI: 10.1002/lt.25451] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
627 George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, Price C, Farrell JJ. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology 2019;19:587-94. [PMID: 31076344 DOI: 10.1016/j.pan.2019.04.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
628 Nakamura Y. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Front Med (Lausanne) 2019;6:119. [PMID: 31192215 DOI: 10.3389/fmed.2019.00119] [Cited by in Crossref: 95] [Cited by in F6Publishing: 100] [Article Influence: 23.8] [Reference Citation Analysis]
629 Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD. Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell 2018;33:1017-1032.e7. [PMID: 29894689 DOI: 10.1016/j.ccell.2018.05.009] [Cited by in Crossref: 88] [Cited by in F6Publishing: 91] [Article Influence: 22.0] [Reference Citation Analysis]
630 Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res 2019;25:5493-502. [PMID: 31126960 DOI: 10.1158/1078-0432.CCR-18-2992] [Cited by in Crossref: 97] [Cited by in F6Publishing: 115] [Article Influence: 24.3] [Reference Citation Analysis]
631 Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X. Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019;17:661-674. [PMID: 31205619 DOI: 10.1016/j.csbj.2019.03.006] [Cited by in Crossref: 194] [Cited by in F6Publishing: 216] [Article Influence: 48.5] [Reference Citation Analysis]
632 Schvartsman G, Taranto P, Glitza IC, Agarwala SS, Atkins MB, Buzaid AC. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol 2019;11:1758835919851663. [PMID: 31205512 DOI: 10.1177/1758835919851663] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
633 Violanti SS, Bononi I, Gallenga CE, Martini F, Tognon M, Perri P. New Insights into Molecular Oncogenesis and Therapy of Uveal Melanoma. Cancers (Basel) 2019;11:E694. [PMID: 31109147 DOI: 10.3390/cancers11050694] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
634 Wu AA, Jaffee E, Lee V. Current Status of Immunotherapies for Treating Pancreatic Cancer. Curr Oncol Rep 2019;21:60. [PMID: 31101991 DOI: 10.1007/s11912-019-0811-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
635 Trommer M, Yeo SY, Persigehl T, Bunck A, Grüll H, Schlaak M, Theurich S, von Bergwelt-Baildon M, Morgenthaler J, Herter JM, Celik E, Marnitz S, Baues C. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. Front Pharmacol 2019;10:511. [PMID: 31156434 DOI: 10.3389/fphar.2019.00511] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
636 Jørgensen N, Persson G, Hviid TVF. The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer. Front Immunol 2019;10:911. [PMID: 31134056 DOI: 10.3389/fimmu.2019.00911] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 15.5] [Reference Citation Analysis]
637 Fritz JM, Lenardo MJ. Development of immune checkpoint therapy for cancer. J Exp Med. 2019;216:1244-1254. [PMID: 31068379 DOI: 10.1084/jem.20182395] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 22.5] [Reference Citation Analysis]
638 Wang S, Qin L, Yamankurt G, Skakuj K, Huang Z, Chen PC, Dominguez D, Lee A, Zhang B, Mirkin CA. Rational vaccinology with spherical nucleic acids. Proc Natl Acad Sci U S A 2019;116:10473-81. [PMID: 31068463 DOI: 10.1073/pnas.1902805116] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 14.8] [Reference Citation Analysis]
639 Luke JJ. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist 2019;24:e1197-211. [PMID: 31064886 DOI: 10.1634/theoncologist.2018-0876] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
640 Motofei IG. Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches. Curr Treat Options Oncol 2019;20:45. [PMID: 31056729 DOI: 10.1007/s11864-019-0643-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
641 Ma Y, Fang W, Zhang Y, Yang Y, Hong S, Zhao Y, Tendolkar A, Chen L, Xu D, Sheng J, Zhao H, Zhang L. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors. Oncologist 2019;24:891-e431. [PMID: 31048330 DOI: 10.1634/theoncologist.2019-0284] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
642 Zhou H, Fu X, Li Q, Niu T. Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails. Front Pharmacol 2019;10:387. [PMID: 31118893 DOI: 10.3389/fphar.2019.00387] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
643 Miranda Poma J, Ostios Garcia L, Villamayor Sanchez J, D'errico G. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events. Allergol Immunopathol (Madr) 2019;47:303-8. [PMID: 29983240 DOI: 10.1016/j.aller.2018.04.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
644 Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Hellmann MD, Postow MA, Callahan MK, Wolchok JD, Merghoub T. Rational design of anti-GITR-based combination immunotherapy. Nat Med 2019;25:759-66. [PMID: 31036879 DOI: 10.1038/s41591-019-0420-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 124] [Article Influence: 29.3] [Reference Citation Analysis]
645 Winkler JK, Buder-Bakhaya K, Dimitrakopoulou-Strauss A, Enk A, Hassel JC. [Malignant melanoma : Current status]. Radiologe 2017;57:814-21. [PMID: 28730266 DOI: 10.1007/s00117-017-0281-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
646 Koelzer VH, Glatz K, Bubendorf L, Weber A, Gaspert A, Cathomas G, Lugli A, Zippelius A, Kempf W, Mertz KD. [The pathology of adverse events with immune checkpoint inhibitors]. Pathologe 2017;38:197-208. [PMID: 28421272 DOI: 10.1007/s00292-017-0281-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
647 Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res 2019;38:156. [PMID: 30975211 DOI: 10.1186/s13046-019-1094-2] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 27.0] [Reference Citation Analysis]
648 Macaulay R, Ahuja A, Ademisoye E, Juarez-Garcia A, Shaw JW. Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective. Clinicoecon Outcomes Res 2019;11:199-219. [PMID: 30936729 DOI: 10.2147/CEOR.S177343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
649 Grenda A, Nicoś M, Szczyrek M, Krawczyk P, Kucharczyk T, Jarosz B, Pankowski J, Sawicki M, Szumiło J, Bukała P, Milanowski J. MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer. Oncol Lett 2019;17:5193-200. [PMID: 31186735 DOI: 10.3892/ol.2019.10207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
650 Abid MB. Could the menagerie of the gut microbiome really cure cancer? Hope or hype. J Immunother Cancer 2019;7:92. [PMID: 30940203 DOI: 10.1186/s40425-019-0561-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
651 Floudas CS, Brar G, Greten TF. Immunotherapy: Current Status and Future Perspectives. Dig Dis Sci 2019;64:1030-40. [PMID: 30830521 DOI: 10.1007/s10620-019-05516-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
652 Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World J Meta-Anal 2019; 7(3): 80-95 [DOI: 10.13105/wjma.v7.i3.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
653 Weiss SA, Wolchok JD, Sznol M. Immunotherapy of Melanoma: Facts and Hopes. Clin Cancer Res 2019;25:5191-201. [PMID: 30923036 DOI: 10.1158/1078-0432.CCR-18-1550] [Cited by in Crossref: 118] [Cited by in F6Publishing: 127] [Article Influence: 29.5] [Reference Citation Analysis]
654 Nikolaou V, Voudouri D, Tsironis G, Charpidou A, Stamoulis G, Triantafyllopoulou I, Panoutsopoulou I, Xidakis E, Bamias A, Samantas E, Aravantinos G, Gogas H, Rigopoulos D, Syrigos K, Stratigos A. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients. Support Care Cancer 2019;27:4535-42. [PMID: 30919155 DOI: 10.1007/s00520-019-04751-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
655 Tolstrup LK, Bastholt L, Zwisler AD, Dieperink KB, Pappot H. Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. J Patient Rep Outcomes 2019;3:19. [PMID: 30900035 DOI: 10.1186/s41687-019-0111-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
656 Lin A, Gorbanev Y, De Backer J, Van Loenhout J, Van Boxem W, Lemière F, Cos P, Dewilde S, Smits E, Bogaerts A. Non-Thermal Plasma as a Unique Delivery System of Short-Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells. Adv Sci (Weinh) 2019;6:1802062. [PMID: 30937272 DOI: 10.1002/advs.201802062] [Cited by in Crossref: 116] [Cited by in F6Publishing: 125] [Article Influence: 29.0] [Reference Citation Analysis]
657 Munhoz RR, Postow MA. Clinical Development of PD-1 in Advanced Melanoma. Cancer J 2018;24:7-14. [PMID: 29360722 DOI: 10.1097/PPO.0000000000000299] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
658 Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol 2019;10:491. [PMID: 30936880 DOI: 10.3389/fimmu.2019.00491] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
659 von Knethen A, Schäfer A, Kuchler L, Knape T, Christen U, Hintermann E, Fißlthaler B, Schröder K, Brandes RP, Genz B, Abshagen K, Pützer BM, Sha LK, Weigert A, Syed SN, Schulz M, Shah AM, Ernst A, Putyrski M, Finkelmeier F, Pesic M, Greten F, Hogardt M, Kempf VAJ, Gunne S, Parnham MJ, Brüne B. Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis. Theranostics 2019;9:2003-16. [PMID: 31037153 DOI: 10.7150/thno.28057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
660 Norton TD, Zhen A, Tada T, Kim J, Kitchen S, Landau NR. Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice. Mol Ther 2019;27:960-73. [PMID: 30962161 DOI: 10.1016/j.ymthe.2019.03.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
661 Teige I, Mårtensson L, Frendéus BL. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB. Front Immunol 2019;10:481. [PMID: 30930905 DOI: 10.3389/fimmu.2019.00481] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
662 Chat V, Ferguson R, Simpson D, Kazlow E, Lax R, Moran U, Pavlick A, Frederick D, Boland G, Sullivan R, Ribas A, Flaherty K, Osman I, Weber J, Kirchhoff T. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunol Immunother 2019;68:897-905. [PMID: 30863922 DOI: 10.1007/s00262-019-02318-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
663 Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A. Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma. Clin Cancer Res 2019;25:3239-46. [PMID: 30824584 DOI: 10.1158/1078-0432.CCR-18-0720] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
664 Maeda T, Yoshino K, Nagai K, Oaku S, Kato M, Hiura A, Hata H. The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma. Acta Oncol 2019;58:379-81. [PMID: 30614355 DOI: 10.1080/0284186X.2018.1541252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
665 Zappasodi R, Merghoub T, Wolchok JD. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell. 2018;33:581-598. [PMID: 29634946 DOI: 10.1016/j.ccell.2018.03.005] [Cited by in Crossref: 282] [Cited by in F6Publishing: 250] [Article Influence: 70.5] [Reference Citation Analysis]
666 Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Del Carmen Gil Cruz C, Pérez Shibayama CI, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser DE, Ludewig B, Levesque MP, Dummer R, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019;7:50. [PMID: 30786924 DOI: 10.1186/s40425-019-0523-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
667 Pelster MS, Amaria RN. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol 2019;11:1758835919830826. [PMID: 30815041 DOI: 10.1177/1758835919830826] [Cited by in Crossref: 77] [Cited by in F6Publishing: 86] [Article Influence: 19.3] [Reference Citation Analysis]
668 Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res 2019;38:87. [PMID: 30777100 DOI: 10.1186/s13046-019-1085-3] [Cited by in Crossref: 116] [Cited by in F6Publishing: 129] [Article Influence: 29.0] [Reference Citation Analysis]
669 Ottaviano M, De Placido S, Ascierto PA. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Arch 2019;474:421-32. [PMID: 30747264 DOI: 10.1007/s00428-019-02538-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
670 Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y, Wu M, Malladi VS, Huang W, Walker W, Palakurthi S, Dranoff G, Hammerman PS, Pecot CV, Wong KK, Akbay EA. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. J Immunother Cancer 2019;7:32. [PMID: 30728077 DOI: 10.1186/s40425-019-0504-5] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 15.5] [Reference Citation Analysis]
671 Suarez-Kelly LP, Levine KM, Olencki TE, Del Campo SEM, Streacker EA, Brooks TR, Karpa VI, Markowitz J, Bingman AK, Geyer SM, Kendra KL, Carson WE. A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma. Cancer Immunol Immunother 2019;68:619-29. [PMID: 30725205 DOI: 10.1007/s00262-019-02308-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
672 Lanier CM, Hughes R, Ahmed T, LeCompte M, Masters AH, Petty WJ, Ruiz J, Triozzi P, Su J, O'Neill S, Watabe K, Cramer CK, Laxton AW, Tatter SB, Wang G, Whitlow C, Chan MD. Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. Neurooncol Pract 2019;6:402-9. [PMID: 31555455 DOI: 10.1093/nop/npz004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
673 Su Q, Zhu EC, Wu JB, Li T, Hou YL, Wang DY, Gao ZH. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. Front Immunol 2019;10:108. [PMID: 30778352 DOI: 10.3389/fimmu.2019.00108] [Cited by in Crossref: 71] [Cited by in F6Publishing: 82] [Article Influence: 17.8] [Reference Citation Analysis]
674 Rahouma M, Baudo M, Yahia M, Kamel M, Gray KD, Elmously A, Ghaly G, Eldessouki I, Abouarab A, Cheriat AN, Karim NA, Mohamed A, Morris J, Gaudino M. Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. J Thorac Dis 2019;11:521-34. [PMID: 30962996 DOI: 10.21037/jtd.2019.01.19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
675 Namikawa K, Yamazaki N. Targeted Therapy and Immunotherapy for Melanoma in Japan. Curr Treat Options Oncol 2019;20:7. [PMID: 30675668 DOI: 10.1007/s11864-019-0607-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
676 Zhang M, Yang J, Hua W, Li Z, Xu Z, Qian Q. Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy. Front Med 2019;13:32-44. [PMID: 30680606 DOI: 10.1007/s11684-018-0678-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
677 Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol 2018;20:674-86. [PMID: 29106665 DOI: 10.1093/neuonc/nox208] [Cited by in Crossref: 252] [Cited by in F6Publishing: 266] [Article Influence: 63.0] [Reference Citation Analysis]
678 Keilholz U, Mehnert JM, Bauer S, Bourgeois H, Patel MR, Gravenor D, Nemunaitis JJ, Taylor MH, Wyrwicz L, Lee KW, Kasturi V, Chin K, von Heydebreck A, Gulley JL. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer 2019;7:12. [PMID: 30651126 DOI: 10.1186/s40425-018-0459-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 12.0] [Reference Citation Analysis]
679 Ma HS, Poudel B, Torres ER, Sidhom JW, Robinson TM, Christmas B, Scott B, Cruz K, Woolman S, Wall VZ, Armstrong T, Jaffee EM. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. Cancer Immunol Res 2019;7:428-42. [PMID: 30642833 DOI: 10.1158/2326-6066.CIR-18-0061] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 16.8] [Reference Citation Analysis]
680 Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci) 2018;6:79-100. [PMID: 30713991 DOI: 10.1142/S2339547818300020] [Cited by in Crossref: 123] [Cited by in F6Publishing: 137] [Article Influence: 30.8] [Reference Citation Analysis]
681 Yusko E, Vignali M, Wilson RK, Mardis ER, Hodi FS, Horak C, Chang H, Woods DM, Robins H, Weber J. Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. Cancer Immunol Res 2019;7:458-65. [PMID: 30635271 DOI: 10.1158/2326-6066.CIR-18-0226] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
682 Giraldo NA, Peske JD, Sautès-fridman C, Fridman WH. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Arch 2019;474:463-74. [DOI: 10.1007/s00428-018-02517-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
683 An Q, Liu Z. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis. BMC Cancer 2019;19:43. [PMID: 30626368 DOI: 10.1186/s12885-018-5259-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
684 Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. J Clin Oncol 2019;37:481-9. [PMID: 30620669 DOI: 10.1200/JCO.18.00766] [Cited by in Crossref: 180] [Cited by in F6Publishing: 189] [Article Influence: 45.0] [Reference Citation Analysis]
685 Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clin Cancer Res 2019;25:2442-9. [PMID: 30617133 DOI: 10.1158/1078-0432.CCR-18-2652] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 14.5] [Reference Citation Analysis]
686 McGinnis GJ, Raber J. CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. Immunotherapy 2017;9:929-41. [PMID: 29338610 DOI: 10.2217/imt-2017-0056] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
687 Zahavi DJ, Weiner LM. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. Int J Mol Sci 2019;20:E158. [PMID: 30621125 DOI: 10.3390/ijms20010158] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
688 Halim AB. Road map to best practices. Biomarkers, Diagnostics and Precision Medicine in the Drug Industry 2019. [DOI: 10.1016/b978-0-12-816121-0.00011-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
689 Funaki S, Shintani Y, Fukui E, Yamamoto Y, Kanzaki R, Ose N, Kanou T, Minami M, Mori E, Okumura M. The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma. Cancer Med 2019;8:216-26. [PMID: 30600651 DOI: 10.1002/cam4.1943] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
690 Lee SS, Loecher M, Puzanov I. Toxicities in Immune Checkpoint Inhibitors. Immune Checkpoint Inhibitors in Cancer 2019. [DOI: 10.1016/b978-0-323-54948-6.00011-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
691 Kalinski P, Basse P. Immune Checkpoint Inhibitors. Immune Checkpoint Inhibitors in Cancer 2019. [DOI: 10.1016/b978-0-323-54948-6.00001-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
692 Rapisuwon S, Qin Y, Roszik J, Carapeto F, Patel S, Carvajal RD. Systemic Therapy for Mucosal, Acral and Uveal Melanoma. Cutaneous Melanoma 2019. [DOI: 10.1007/978-3-319-46029-1_62-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
693 Lu X, Shen X. Advances in Research on Immunological Checkpoint Inhibitors in Immunotherapy of Liver Cancer. IJCM 2019;10:62-69. [DOI: 10.4236/ijcm.2019.102006] [Reference Citation Analysis]
694 Grimaldi AM, Ascierto PA. Melanoma. International Manual of Oncology Practice 2019. [DOI: 10.1007/978-3-030-16245-0_34] [Reference Citation Analysis]
695 Prieto-granada CN, Van Arnam J, Shah KK, Andea AA, Lazar AJ. Genomic Applications in Melanoma. Genomic Applications in Pathology 2019. [DOI: 10.1007/978-3-319-96830-8_34] [Reference Citation Analysis]
696 Ascierto PA. Immunotherapies and Novel Combinations. Oncogenomics 2019. [DOI: 10.1016/b978-0-12-811785-9.00045-4] [Reference Citation Analysis]
697 Abri K, Daud AI. Combinatorial Approach to Treatment of Melanoma. Melanoma 2019. [DOI: 10.1007/978-1-4614-7147-9_18] [Reference Citation Analysis]
698 Lee S, Bhatia S. Immune Checkpoints. Immune Checkpoint Inhibitors in Cancer 2019. [DOI: 10.1016/b978-0-323-54948-6.00002-0] [Reference Citation Analysis]
699 Sullivan RJ, Hodi FS. Introduction to Melanoma Immunology. Melanoma 2019. [DOI: 10.1007/978-1-4614-7322-0_36-1] [Reference Citation Analysis]
700 Sullivan RJ, Hodi FS. Melanoma Immunology and Immunotherapy. Melanoma 2019. [DOI: 10.1007/978-1-4614-7147-9_36] [Reference Citation Analysis]
701 Jeung H, Oh SE, Kim JH. Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors. J Rheum Dis 2019;26:221. [DOI: 10.4078/jrd.2019.26.4.221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
702 Ascierto PA, Atkins MB. Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. Cutaneous Melanoma 2019. [DOI: 10.1007/978-3-319-46029-1_61-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
703 Pavlick A, Weber J. Managing Checkpoint Inhibitor Symptoms and Toxicity. Cutaneous Melanoma 2019. [DOI: 10.1007/978-3-319-46029-1_60-1] [Reference Citation Analysis]
704 Sharma A, Campbell M, Yee C, Goswami S, Sharma P. Immunotherapy of Cancer. Clinical Immunology 2019. [DOI: 10.1016/b978-0-7020-6896-6.00077-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
705 Keshavarz-fathi M, Rezaei N. Obstacles in the Development of Therapeutic Cancer Vaccines. Vaccines for Cancer Immunotherapy 2019. [DOI: 10.1016/b978-0-12-814039-0.00012-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
706 Murshed H. Immunotherapy. Fundamentals of Radiation Oncology 2019. [DOI: 10.1016/b978-0-12-814128-1.00010-6] [Reference Citation Analysis]
707 Oliveira LJ, Gongora AB, Barbosa FG, dos Anjos C, Munhoz RR. Atypisches Ansprechen mit Pseudoprogression im Knochen unter Nivolumab bei einem Patienten mit fortgeschrittenem kutanem Plattenepithelkarzinom. Kompass Dermatol 2019;7:149-153. [DOI: 10.1159/000501250] [Reference Citation Analysis]
708 Sullivan RJ, Hodi FS. Melanoma Immunology and Immunotherapy. Melanoma 2019. [DOI: 10.1007/978-1-4614-7322-0_36-2] [Reference Citation Analysis]
709 Malesa A, Nowak J, Skórka K, Karp M, Giannopoulos K. Immunoterapia z użyciem przeciwciał monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. Acta Haematologica Polonica 2018;49:207-227. [DOI: 10.2478/ahp-2018-0025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
710 Hyams DM, Cook RW, Buzaid AC. Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. J Surg Oncol 2019;119:175-86. [PMID: 30548543 DOI: 10.1002/jso.25319] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
711 Ma K, Lu Y, Jiang S, Tang J, Li X, Zhang Y. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. Front Pharmacol 2018;9:1430. [PMID: 30618738 DOI: 10.3389/fphar.2018.01430] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 11.0] [Reference Citation Analysis]
712 Pan M, Alavi M, Herrinton LJ. Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. Perm J 2018;22:17-149. [PMID: 29616914 DOI: 10.7812/TPP/17-149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
713 Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol 2019;145:511-21. [PMID: 30539281 DOI: 10.1007/s00432-018-2819-x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 127] [Article Influence: 24.4] [Reference Citation Analysis]
714 Angell HK, Lee J, Kim KM, Kim K, Kim ST, Park SH, Kang WK, Sharpe A, Ogden J, Davenport A, Hodgson DR, Barrett JC, Kilgour E. PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. Oncoimmunology 2019;8:e1544442. [PMID: 30729066 DOI: 10.1080/2162402X.2018.1544442] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
715 Sahni S, Valecha G, Sahni A. Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. Cureus 2018;10:e3700. [PMID: 30788189 DOI: 10.7759/cureus.3700] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
716 Manton T, Tillman B, McHugh J, Bellile E, McLean S, McKean E. Sinonasal Melanoma: A Single Institutional Analysis and Future Directions. J Neurol Surg B Skull Base 2019;80:484-92. [PMID: 31534890 DOI: 10.1055/s-0038-1676355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
717 Karadurmus N, Nahit Sendur MA, Karaca B, Olmez OF, Hacibekiroglu I, Coskun HS, Degirmencioglu S, Kemal Y, Kilickap S, Sumbul AT, Aydin B, Turna H, Kaplan MA, Babacan N, Demirci U, Ata A, Erdem D, Ozet A, Abali H. Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients. Journal of Oncological Sciences 2018;4:125-9. [DOI: 10.1016/j.jons.2018.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
718 Wei M, Liu X, Cao C, Yang J, Lv Y, Huang J, Wang Y, Qin Y. An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma. BMB Rep 2018;51:572-7. [DOI: 10.5483/bmbrep.2018.51.11.076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
719 Furubayashi N, Negishi T, Uozumi T, Takamatsu D, Shiraishi K, Hirose D, Nakamura M. Isolated adrenocorticotropic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: A case report. Mol Clin Oncol 2019;10:304-8. [PMID: 30680212 DOI: 10.3892/mco.2018.1781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
720 Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, Bianchi HO, Audehm S, Wagner R, Bräunlein E, Stelzl A, Bassermann F, Weichert W, Weber W, Schwaiger M, D'Alessandria C, Krackhardt AM. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics 2018;8:6070-87. [PMID: 30613283 DOI: 10.7150/thno.27275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
721 Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity 2018;48:434-52. [PMID: 29562194 DOI: 10.1016/j.immuni.2018.03.014] [Cited by in Crossref: 864] [Cited by in F6Publishing: 922] [Article Influence: 172.8] [Reference Citation Analysis]
722 Zhulikov YA, Samoylenko IV, Demidov LV. Mechanisms of resistance to anti-Pd-1 therapy in metastatic cutaneous melanoma. Rossijskij bioterapevtičeskij žurnal 2018;17:34-46. [DOI: 10.17650/1726-9784-2018-17-1-34-46] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
723 Oliveira LJC, Gongora ABL, Barbosa FG, Dos Anjos CH, Munhoz RR. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. J Immunother Cancer 2018;6:130. [PMID: 30482243 DOI: 10.1186/s40425-018-0444-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
724 Verma V, Sprave T, Haque W, Simone CB 2nd, Chang JY, Welsh JW, Thomas CR Jr. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer 2018;6:128. [PMID: 30470252 DOI: 10.1186/s40425-018-0442-7] [Cited by in Crossref: 155] [Cited by in F6Publishing: 165] [Article Influence: 31.0] [Reference Citation Analysis]
725 Martin Lluesma S, Graciotti M, Chiang CL, Kandalaft LE. Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies? Vaccines (Basel) 2018;6:E79. [PMID: 30477198 DOI: 10.3390/vaccines6040079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
726 Lin W, Chen M, Hong L, Zhao H, Chen Q. Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. Front Oncol 2018;8:532. [PMID: 30519541 DOI: 10.3389/fonc.2018.00532] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
727 Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C. The clinical role of the TME in solid cancer. Br J Cancer 2019;120:45-53. [PMID: 30413828 DOI: 10.1038/s41416-018-0327-z] [Cited by in Crossref: 185] [Cited by in F6Publishing: 201] [Article Influence: 37.0] [Reference Citation Analysis]
728 Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226. [PMID: 30409774 DOI: 10.1136/bmj.k4226] [Cited by in Crossref: 220] [Cited by in F6Publishing: 227] [Article Influence: 44.0] [Reference Citation Analysis]
729 Kim KB, Semrad T, Schrock AB, Ali SM, Ross JS, Singer M, Kashani-Sabet M. Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an RAF1 Fusion. JCO Precis Oncol 2018;2:1-6. [PMID: 35135096 DOI: 10.1200/PO.17.00138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
730 Ameratunga M, Xu W, Lopez J. Personalized Cancer Immunotherapy: Today’s Challenge and Tomorrow’s Promise. Journal of Immunotherapy and Precision Oncology 2018;1:56-67. [DOI: 10.4103/jipo.jipo_13_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
731 Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, Smylie M, Verma S. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol 2018;25:e373-84. [PMID: 30464687 DOI: 10.3747/co.25.3840] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 14.2] [Reference Citation Analysis]
732 Alongi F, Fiorentino A, Gregucci F, Corradini S, Giaj-Levra N, Romano L, Rigo M, Ricchetti F, Beltramello A, Lunardi G, Mazzola R, Ruggieri R. First experience and clinical results using a new non-coplanar mono-isocenter technique (HyperArc™) for Linac-based VMAT radiosurgery in brain metastases. J Cancer Res Clin Oncol 2019;145:193-200. [PMID: 30382369 DOI: 10.1007/s00432-018-2781-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
733 Iida Y, Salomon MP, Hata K, Tran K, Ohe S, Griffiths CF, Hsu SC, Nelson N, Hoon DSB. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. BMC Cancer 2018;18:1054. [PMID: 30373548 DOI: 10.1186/s12885-018-4977-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
734 Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therap Adv Gastroenterol 2018;11:1756284818808086. [PMID: 30377451 DOI: 10.1177/1756284818808086] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
735 He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR. TIM-3, a promising target for cancer immunotherapy. Onco Targets Ther 2018;11:7005-9. [PMID: 30410357 DOI: 10.2147/OTT.S170385] [Cited by in Crossref: 117] [Cited by in F6Publishing: 127] [Article Influence: 23.4] [Reference Citation Analysis]
736 Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 2018;109:3583-90. [PMID: 30230649 DOI: 10.1111/cas.13800] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 15.2] [Reference Citation Analysis]
737 Pfannenstiel LW, McNeilly C, Xiang C, Kang K, Diaz-Montero CM, Yu JS, Gastman BR. Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. Oncoimmunology 2019;8:e1507669. [PMID: 30546944 DOI: 10.1080/2162402X.2018.1507669] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
738 Tyrrell H, Payne M. Combatting mucosal melanoma: recent advances and future perspectives. Melanoma Manag 2018;5:MMT11. [PMID: 30459941 DOI: 10.2217/mmt-2018-0003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
739 Anderson D, Beecher G, Nathoo N, Smylie M, McCombe JA, Walker J, Jassal R. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors. Neurooncol Pract 2019;6:340-5. [PMID: 31555448 DOI: 10.1093/nop/npy039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
740 Duan J, Xie Y, Qu L, Wang L, Zhou S, Wang Y, Fan Z, Yang S, Jiao S. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy. J Immunother Cancer 2018;6:100. [PMID: 30285868 DOI: 10.1186/s40425-018-0418-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
741 Chen Y, Sun J, Huang Y, Lu B, Li S. Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. Mol Pharm 2018;15:5162-73. [PMID: 30222360 DOI: 10.1021/acs.molpharmaceut.8b00717] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
742 Ward FJ, Dahal LN, Abu-Eid R. On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. Front Immunol 2018;9:2182. [PMID: 30319637 DOI: 10.3389/fimmu.2018.02182] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
743 Shi F, Chang H, Zhou Q, Zhao YJ, Wu GJ, Song QK. Distribution of CD4+ and CD8+ exhausted tumor-infiltrating lymphocytes in molecular subtypes of Chinese breast cancer patients. Onco Targets Ther. 2018;11:6139-6145. [PMID: 30288049 DOI: 10.2147/ott.s168057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
744 Mylvaganam GH, Chea LS, Tharp GK, Hicks S, Velu V, Iyer SS, Deleage C, Estes JD, Bosinger SE, Freeman GJ, Ahmed R, Amara RR. Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. JCI Insight 2018;3:122940. [PMID: 30232277 DOI: 10.1172/jci.insight.122940] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 11.2] [Reference Citation Analysis]
745 Friedlander P, Wood K, Wassmann K, Christenfeld AM, Bhardwaj N, Oh WK. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. J Immunother Cancer 2018;6:90. [PMID: 30227886 DOI: 10.1186/s40425-018-0408-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
746 Redman JM, Steinberg SM, Gulley JL. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. J Immunother Cancer 2018;6:91. [PMID: 30227893 DOI: 10.1186/s40425-018-0409-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
747 Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother 2018;67:1833-44. [PMID: 30191256 DOI: 10.1007/s00262-018-2241-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
748 Boothe D, Clyde JW, Christensen M, Patel SB, Lloyd S. A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy. J Radiat Oncol 2018;7:223-232. [DOI: 10.1007/s13566-018-0351-x] [Reference Citation Analysis]
749 Marquardt JU, Vogel A. Update zur systemischen Therapie bei fortgeschrittenem hepatozellulärem Karzinom. Onkologe 2018;24:711-718. [DOI: 10.1007/s00761-018-0404-1] [Reference Citation Analysis]
750 Jiang R, Xu L, Huang Y, Fang C, Guo H, Li S, Wu J, Du Z. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report. Pancreas 2018;47:e53-4. [PMID: 30113432 DOI: 10.1097/MPA.0000000000001107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
751 Appelbaum J, Wells D, Hiatt JB, Steinbach G, Stewart FM, Thomas H, Nghiem P, Kapur RP, Thompson JA, Bhatia S. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 2018;6:82. [PMID: 30170630 DOI: 10.1186/s40425-018-0396-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
752 Yamaguchi K, Mishima K, Ohmura H, Hanamura F, Ito M, Nakano M, Tsuchihashi K, Ota SI, Wada N, Uchi H, Ariyama H, Kusaba H, Niiro H, Akashi K, Baba E. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody. Cancer Sci 2018;109:3032-42. [PMID: 30066977 DOI: 10.1111/cas.13758] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
753 Deniz B, Altincatal A, Ambavane A, Rao S, Doan J, Malcolm B, Michaelson MD, Yang S. Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. PLoS One 2018;13:e0203406. [PMID: 30161244 DOI: 10.1371/journal.pone.0203406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
754 Kondo T, Nomura M, Otsuka A, Nonomura Y, Kaku Y, Matsumoto S, Muto M. Predicting marker for early progression in unresectable melanoma treated with nivolumab. Int J Clin Oncol 2019;24:323-7. [PMID: 30168088 DOI: 10.1007/s10147-018-1345-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
755 LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol 2018;200:375-83. [PMID: 29311378 DOI: 10.4049/jimmunol.1701044] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 17.0] [Reference Citation Analysis]
756 Collins JM, Redman JM, Gulley JL. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. Expert Rev Vaccines 2018;17:697-705. [PMID: 30058393 DOI: 10.1080/14760584.2018.1506332] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
757 Du Four S, Janssen Y, Michotte A, Van Binst AM, Van den Begin R, Duerinck J, Neyns B. Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab. Cancer Med 2018;7:4870-9. [PMID: 30133176 DOI: 10.1002/cam4.1726] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
758 Goldman JW, Abdalla B, Mendenhall MA, Sisk A, Hunt J, Danovitch GM, Lum EL. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report. BMC Nephrol 2018;19:210. [PMID: 30126374 DOI: 10.1186/s12882-018-1003-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
759 Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104. [PMID: 30115069 DOI: 10.1186/s13045-018-0647-8] [Cited by in Crossref: 172] [Cited by in F6Publishing: 188] [Article Influence: 34.4] [Reference Citation Analysis]
760 Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Front Immunol 2018;9:1878. [PMID: 30158932 DOI: 10.3389/fimmu.2018.01878] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 15.8] [Reference Citation Analysis]
761 Dalgleish AG, Mudan S, Fusi A. Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity. J Transl Med 2018;16:227. [PMID: 30107850 DOI: 10.1186/s12967-018-1602-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
762 O'Connor JM, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncol 2018;4:e180798. [PMID: 29800974 DOI: 10.1001/jamaoncol.2018.0798] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 12.8] [Reference Citation Analysis]
763 Skelton WP 4th, Parekh H, Starr JS, Trevino J, Cioffi J, Hughes S, George TJ Jr. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer 2018;49:1-8. [PMID: 29110227 DOI: 10.1007/s12029-017-0021-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
764 Duan J, Wang Y, Jiao S. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. Cancer Med 2018;7:4517-29. [PMID: 30088347 DOI: 10.1002/cam4.1722] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
765 Zhu Y, Zhao F, Li Z, Yu J. Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Manag Res 2018;10:2475-88. [PMID: 30122997 DOI: 10.2147/CMAR.S167400] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
766 Badiyan SN, Roach MC, Chuong MD, Rice SR, Onyeuku NE, Remick J, Chilukuri S, Glass E, Mohindra P, Simone CB 2nd. Combining immunotherapy with radiation therapy in thoracic oncology. J Thorac Dis 2018;10:S2492-507. [PMID: 30206494 DOI: 10.21037/jtd.2018.05.73] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
767 Yao H, Wang H, Li C, Fang JY, Xu J. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Front Immunol 2018;9:1774. [PMID: 30105035 DOI: 10.3389/fimmu.2018.01774] [Cited by in Crossref: 69] [Cited by in F6Publishing: 79] [Article Influence: 13.8] [Reference Citation Analysis]
768 Zhang D, Lin J, Chao Y, Zhang L, Jin L, Li N, He R, Ma B, Zhao W, Han C. Regulation of the adaptation to ER stress by KLF4 facilitates melanoma cell metastasis via upregulating NUCB2 expression. J Exp Clin Cancer Res 2018;37:176. [PMID: 30055641 DOI: 10.1186/s13046-018-0842-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
769 Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J, Hudgens CW, Van Arnam J, Wargo JA, Esmaeli B, Tetzlaff MT. High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. Oncoimmunology 2018;7:e1475874. [PMID: 30228943 DOI: 10.1080/2162402X.2018.1475874] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
770 Giordano FA, Veldwijk MR, Herskind C, Wenz F. Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math. Strahlenther Onkol 2018;194:873-5. [PMID: 30030581 DOI: 10.1007/s00066-018-1341-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
771 Lopez AT, Geskin L. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. Oncologist 2018;23:1119-26. [PMID: 30018132 DOI: 10.1634/theoncologist.2018-0128] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 10.8] [Reference Citation Analysis]
772 Bastiaannet E, Battisti N, Loh KP, de Glas N, Soto-Perez-de-Celis E, Baldini C, Kapiteijn E, Lichtman S. Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. J Geriatr Oncol 2019;10:389-97. [PMID: 30025821 DOI: 10.1016/j.jgo.2018.06.009]